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The title alludes to Aldous Huxley's dystopia in Brave New World. ALDOUS
(1932). In his novel, science has become the panacea for
many of society's ills; thus, its techniques and philosophies have been applied to every facet
of human life. Eugenics has triumphed to the point where babies, according to the needs
of society, are "decanted." See generally id. (describing the "decanting" process; this
author sees it as homologous to baking and animal husbandry). Although a rather
controlled and emotionless vision of the future, Huxley portrays the ills of science and
technology in his society with the underlying themes of community, identity, and stability.
Id. at 1 (referring to the motto for Huxley's utopian World State: "Community, Identity,
Stability"). Just as this comment inquires into those ills that may destroy mankind, it also
explores how science, specifically in the field of pharmacogenomics, may improve the
caliber of human beings.
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INTRODUCTION

"Biology will become an engine of transformation of our society...
Instead of guessing how we differ one from another, we will understand
and be able to tailor our life experiences to our inheritance. We will also
be able, to some extent, to control that inheritance." ' However, this engine is a double-edge sword.
[W]e have our stability to think of. We don't want to change. Every
change is a menace to stability. That's another reason why we're so
chary of applying new inventions. Every discovery in pure science is
potentially subversive; even science must sometimes be treated as a
possible enemy. Yes, even science.2
Thus, we have this engine, which has far-reaching and limitless possibilities to enhance mankind's standard of living and understanding of
life. Yet, it opens the door for exclusion through distinctions, which are
drawn from our genetic predispositions.' These exclusions, based on purported behavioral dispositions and anticipated health risks, are commonly
associated with particular races or ethnic groups.4
1. Ralph Brave, Governing the Genome, NATION, Dec. 10, 2001, at 18, 18 (quoting Cal
published human
genome sequence).

Tech president and Nobelist David Baltimore from his preface to the

2. ALDOUs HUXLEY, BRAVE NEW WORLD 231 (1932).
3. Dorothy Nelkin, A Brief History of the PoliticalWork of Genetics, 42 JURIMETRICS
J. 121, 122 (2002). Mutations, which are changes in the sequences of the genes' chemistry,
account for diseases characteristic in particular populations. Id.; see also STEDMAN'S MEDICAL DICIONARY 1166 (27th ed. 2000) [hereinafter STEDMAN'S].
4. Nelkin, supra note 3, at 122. For example, population stereotypes have historically
played a role in immigration legislation. Id. at 131. In response to anti-immigration rhetoric claiming potential immigrants as biologically inferior, intrinsically unhealthy, and potentially draining on public services, Congress passed the Immigration Act of 1924, which
restricted immigration from Central, Eastern and Southern Europe. Immigration Act of
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This comment will explore the double-edged sword of biology, particularly in the field of pharmacogenomics. Pharmacogenomics uses the
knowledge that ethnic variation plays a part in human drug responses,
thereby creating the need for population-specific research to study this
effect of genetic diversity on human responses to drugs and other chemical substances.5 Part I addresses preliminary issues, which include a discussion of scientific terminology and theories pertinent to this comment,
as well as an overview of pharmacogenomics. Part II delves into the historical and sociological perspectives pertinent to this issue. Part III reviews particular state and federal laws relating to genetic testing and
information. This section includes an application of current laws to
pharmacogenomics. Part IV proposes a uniform law to alleviate people's
fear of potential discrimination. The abstractness of science to the general public evokes a fear that even the decoded human genome cannot
alleviate without the regulations and protections afforded by the law.
A.

Laying the Foundation

The Human Genome Project (HGP) 6 sought to demystify the human
genetic make-up by mapping and sequencing the genes on the human
DNA.7 One of the goals for the Human Genome Project was to determine the gene associated with specific physiological functions.8 As a re-

1924, ch. 190, 43 stat. 153 (repealed 1952); Nelkin, supra note 3, at 131. Although the
Immigration Act of 1924 has been repealed, similar arguments have resurfaced among
anti-immigration groups. Nelkin, supra note 3, at 131.
5. See Wendell W. Weber, Scientific Rationales for Population-Specific Genetic Research: Pharmacogeneticsin Indigenous Peoples, 42 JURIMETRICS J. 141, 141-43 (2002).
6. J. Craig Venter et al., The Sequence of the Human Genome, 291 Scl. 1304, 1305
(2001). The modern history of DNA sequencing began in 1977 when the technology was
developed to determine an organism's genetic sequence and when the first human gene
was isolated and sequenced. Id. In 1985, scientists finally presented the first formal proposal for a project to determine the human genome's complete nucleotide sequence. Id.
Though an international endeavor, the United States did not officially initiate its own HGP
until 1990. Id. The United States created its HGP under the direction of the National
Institutes of Health and the United States Department of Energy. Id. Although the penultimate goal was to decode the human genome, the HGP sought to ultimately understand current scientific and medical mysteries (e.g., the interplay between heredity and
environment, human evolution, causation of diseases). Id. See generally Leslie Roberts,
ControversialFrom the Start, 291 Sci. 1182 (2001) (outlining chronologically the researchers, who contributed to and furthered the HGP mission, and their achievements).
7. ERIC S. GRACE, BIOTECHNOLOGY UNZIPPED: PROMISES AND REALITIES 69 (1997);
see Anita LaFrance Allen, Genetic Testing, Nature, and Trust, 27 SETON HALL L. REV. 887,
887 (1997); Michael R. Costa, Note, Genetic Testing: InternationalStrategies to Prevent Po-

tential Discrimination in Insurance Risk Classification, 20

SUFFOLK TRANSNAT'L

L.

REV.

109, 113 (1996).
8. Allen, supra note 7, at 887.
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suit of this endeavor, a technological revolution, specifically in
biotechnology, occurred. 9 Issues regarding benefits, risks, and regulation
arose with this revolution. The HGP also created new fields within

biotechnology.1"

The discovery of the double-helix model of deoxyribonucleic acid
(DNA) in 1953 by Watson and Crick marked the beginning of this era of
modern biotechnology." By the 1970s, scientists were able to isolate a
given piece of DNA, which in turn led to the development of genetic

engineering, also called recombinant DNA technology. Recombinant
DNA technology involves the process of gene splicing, that is, the combi-

nation of heterologous DNA pieces for the purpose of cloning, analysis,
and design of potential genetic therapeutics, thereby revolutionizing
modern biotechnology with its ability to alter genetic material. 2 Recombinant DNA technology transformed food production, " industry, 4 and

9. See generally JEREMY RIFKIN, THE BIOTECH CENTURY: HARNESSING THE GENE
AND REMAKING THE WORLD (1998) (analyzing how the new genetic engineering technologies have revolutionized biotechnology).
10. Biotechnology is the industrial use of "biological materials to create products for
the benefits of human beings." SUSAN ALDRIDGE, THE THREAD OF LIFE: THE STORY OF
GENES AND GENETIC ENGINEERING 185 (1996); Louis Levine, Biotechnology, in
MICROSOFT ENCARTA ONLINE ENCYCLOPEDIA, at http://encarta.msn.com/encnet/refpages/
RefArticle.aspx?refid=761575885 (last visited Sept. 27, 2002). This field applies the techniques of biochemistry, biophysics, cellular biology, and molecular biology to address practical issues related to agriculture, the environment, and human beings. STEDMAN'S, supra
note 3, at 207. It uses genetic technologies, like recombinant DNA, to produce useful
molecules, or to alter biologic processes in order to enhance some desired property. Id. Its
history dates back to about 5000 B.C. in the area of food production and medicine. See
ALDRIDGE, supra, at 185 (discussing the fermentation of fruits and grains to make wine,
beer, and spirits and describing the use of Penicillin by Egyptians who placed moldy bread
on infected wounds); Levine, supra (growing maize in Mexico). Thus, the major application of biotechnology had been in the field of agriculture, where for over 10,000 years
humanity has engaged in such biotechnological activities as animal husbandry and plant
breeding.

TABITHA M. POWLEDGE,

NATIONAL INSTITUTE OF GENERAL MEDICAL SCI-

BASICS 52 (2001). Now, however, the
term "biotechnology" generally refers to a scientific approach to produce living organisms
with new traits (e.g., cloning, recombinant DNA, molecular biology, genomic sequencing).
See id.
11. GRACE, supra note 7, at 16; Timeline: A History of the Human Genome Project,
291 ScI. 1195, 1195 (Leslie Roberts ed., 2001) [hereinafter Timeline]; Levine, supra note 10.
12. Levine, supra note 10; Genetic Engineering, in MICROSOFT ENCARTA ONLINE ENCYCLOPEDIA, at http://encarta.msn.com/encnet/refpages/RefArticle.aspxrefid=761557775
(last visited Sept. 27, 2002). In other words, recombinant DNA is altered DNA resulting
from the insertion, through biologic, chemical, or enzymatic means, of a partial or whole
sequence of DNA not originally present in the original DNA chain. STEDMAN'S, supra
note 3, at 476.
13. Philip L. Bereano, Some Environmentaland Ethical Considerationsof Genetically
Engineered Plants and Foods, in CHANGING NATURE'S COURSE: THE ETHICAL CHALENCES, NATIONAL INSTITUTE OF HEALTH, GENETIC
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medicine.' 5 With advances in areas such as recombinant DNA technology, combinatorial chemistry, and molecular biology, 1997 saw the emer-

gence of pharmacogenomics.' 6

1. The Scientific Background
In order to understand the concepts underlying pharmacogenomics, a

basic understanding of the human genome is in order. The human genome template varies slightly among individuals due to minute variations
from single nucleotide polymorphisms (SNPs). 17 Twenty-three pairs of
chromosomes are collectively known as the "human genome." 18 DNA

strands, which make up these chromosomes, have building blocks consisting of four different bases: adenine, thymine, cytosine, and guanine.1 9
These bases, combined with a phosphate and sugar group, create a unit
called a "nucleotide," which is the DNA's fundamental component.2 °
Random mutations - harmful, good, and neutral - commonly occur during DNA replication. It is this combination of alleles - "the alternative
forms of a gene" - that makes each individual unique. 2 Therefore,
polymorphisms are the variations within the DNA sequence of a popula-

LENGE OF BIOTECHNOLOGY 27, 29 (Gerhold K. Becker ed., 1996) (explaining how the use
of recombinant bovine growth hormone in cows increased milk production).
14. Genetic Engineering,supra note 12 (discussing how genetically altered microbes
are used to break down garbage and petroleum products in industrial waste). See generally
ALDRIDGE, supra note 10, at 232-36 (identifying the use of biotechnology in various
industries).
15. See George P Smith, II & Thaddeus J. Burns, Genetic Determinism or Genetic
Discrimination,11 J. CONTEMP. HEALTH L. & POL'Y 23, 33 (1994) [hereinafter Smith &
Burns] (explaining how, in medicine, gene therapy is used to replace deficient genes). See

generally ALDRIDGE, supranote 10, at 187-92 (describing biotechnology's impact on drugs,
vaccines, and antibodies); Genetic Engineering,supra note 12 (discussing other uses of biotechnology in medicine).

16. See Ian J. Mehr, Pharmacogenomics and Industry Change, 9 APPLIED CLINICAL
TRIALS 34 (2000). Pharmacogenomics relates to the genetic determination of variations in
response to drugs in humans or laboratory organisms. STEDMAN'S, supra note 3, at 1360.
17. Marc Wortman, Medicine Gets Personal, 104 TECH. REV. 72, 72-73 (2001);
Medicine Made to Match Genetic Profile, DRUG WEEK, Mar. 9, 2001, at 3 [hereinafter
Medicine Made to Match].
18. Lee M. Silver, The Meaning of Genes and "Genetic Rights," 40 JURIMETRICS J. 9,
13 (1999).
19. GRACE, supra note 7, at 16-17; Robert Snedden, The Challenge of Pharmacogenetics and Pharmacogenomics,9 NEW GENETICS & SOCIETY 145, 156 (2000).
20. GRACE, supra note 7, at 25; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES, NATIONAL INSTITUTE OF HEALTH, THE CHEMISTRY OF HEALTH 7-8 (2000); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES, NATIONAL INSTITUTE OF HEALTH,
THE STRUCTURES OF LIFE 12-13 (2000) [hereinafter STRUCTURES OF LIFE]; POWLEDGE,

supra note 10, at 52.
21. Silver, supra note 18, at 13.
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tion. 2 The single nucleotide polymorphisms, which are variations in single base pairs, are the small genetic mutations in the DNA.2 3 These
random mutations occur to create, within a population, the greatest
source of variability.2 4
This genetic diversity, specifically in genes coding for metabolic pathways affecting metabolism, contributes to the differing drug responses in
individuals and subpopulations.25 Although genetics contributes to 85%
of an individual's reaction to drugs, pharmaceutical companies design and
market drugs to all patients.26 Pharmacogenomics hopes to counter this
broad-spectrum approach by gearing drugs to specific patient
populations.2 7
2.

An Introduction to Pharmacogenomics

Pharmacogeneticsis a combination of pharmacology and genetics. 28 Its
objective is to personalize medicine through safer and more effective
drugs tailored to an individual's unique genetic code.2 9 Pharmacogenomics merges pharmacogeneticswith genomic technology to achieve this

22. Timeline, supra note 11, at 1195.
23. Id.; Medicine Made to Match, supra note 17, at 3-4.
24. ALDRIDGE, supra note 10, at 245; Timeline, supra note 11, at 1195; Beth Schachter,
Pharming the Genome, HMS BEAGLE: THE BIOMED MAGAZINE, Oct. 30, 1998, available

at http://www.nasw.org/users/bschachter/Pharming.html (last visited Oct. 24, 2002).
25. Wortman, supra note 17, at 72; Snedden, supra note 19, at 148; Medicine Made to
Match, supra note 17, at 3; Cynthia Robbins-Roth, Tailor-Made Drugs, FORBES, July 6,
1998, at 172. Genes do not operate in a vacuum; rather, they interact with other genes,
their gene products, and gene products. Leena Peltonen & Victor A. McKusick, Dissecting

Human Disease in the Postgenomic Era, 291 Sci. 1224, 1226 (2001). This operation results
in symptoms varying among patients with the same disease. Id.
26. Snedden, supra note 19, at 147. See generally Wortman, supra note 17 (discussing
how pharmaceutical companies will transition from the "one size fits all" drugs to personalized medicine); Leah E. Perry, How Pharmacogenomics Will Change Drug Marketing,
DRUG Topics, May 7, 2001, at 70 (comparing the present market of blockbuster drugs with
the future trend toward narrow spectrum drugs). Other factors, aside from genetic influences affecting a person's reaction to medication, include the expressed symptoms to the
disease, the progression of the disease, the "presence of any concurrent disease conditions
or concomitant use of other medication, and tolerance of potential side effects." Lars
Noah, The Coming PharmacogenomicsRevolution: Tailoring Drugs to Fit Patients' Genetic
Profiles, 43 JURIMETRICS 1, 2 (2002); see also Alun McCarthy, Pharmacogenetics:Implications for Drug Development, Patients and Society, 9 NEW GENETICS & SOCIETY 135, 138
(2000) (listing the "amount and rate of medicine absorption [and] rate of drug metabolism
and elimination" as other factors influencing a patient's response to medication).
27. Snedden, supra note 19, at 147; see Wortman, supranote 17, at 74, 78; Perry, supra
note 26, at 70.
28. Snedden, supra note 19, at 145.
29. Id.; Medicine Made to Match, supra note 17, at 3.
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goal. ° It uses genetic technology to understand how a patient's DNA
interacts with a drug.3 1
With this emerging field of pharmacogenomics comes possible benefits
and potentially problematic issues. Benefits include improving drug effectiveness,32 reducing adverse drug reactions,33 determining which drugs
will work optimally for patients,3 4 and allowing continued use of drugs
that may work for one subpopulation but not another.35 Issues include
the potential misuse of genetic information for healthcare and employment, the effect on large pharmaceutical companies who rely on "blockbuster drugs, '"36 and the international and domestic regulation of
pharmacogenomics. The issues of genetic determinism and genetic discrimination must also be considered.3 7
As previously stated, pharmacogenomics seeks to design drugs for specific individuals or subpopulations. Pharmacogenetic traits are linked to
ethnicity. 38 For example, genetic variation in the production of the en-

30. Snedden, supra note 19, at 146.
31. See Robbins-Roth, supra note 25, at 172; Gary Stix, PersonalPills, 279 Sci. AM.
17, 17-18 (1998); Journal Debuts Theme Issue on Pharmacogenetics, Pharmacogenomics,
GENOMICS & GENETICS WEEKLY, Feb. 2, 2001, at 10 [hereinafter JournalDebuts Theme].
32. See Cinda Becker, The DNA Rx: Advances in Genetics Give PhysiciansAbility to
Tailor Drugs to Patients' Unique Makeup, MODERN HEALTHCARE, Aug. 28, 2000, at 24;
William E. Evans & Mary V. Relling, Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics, 286 Sci. 487, 487 (1999); Robert McCarthy, Can Drug
Industry Hold on Until PharmacogenomicsMove In?, DRUG Topics, Apr. 17, 2000, at 27.
33. See Becker, supra note 32, at 24; McCarthy, supra note 32, at 27.
34. See Evans & Relling, supra note 32, at 487; Get Set for Pharmacogenomics,APPLIED GENETICS NEWS, Aug. 1, 1997 (LEXIS, Applied Genetic News, Drug Discovery);
The Right Medicine: Pharmacogenomics Could Revolutionize the PharmaceuticalIndustry,
MED AD NEWS, June 1, 1999, at 3 [hereinafter The Right Medicine].
35. Snedden, supra note 19, at 149; Wortman, supra note 17, at 72; Journal Debuts
Theme, supra note 31, at 10; Robbins-Roth, supra note 25, at 172.
36. Definitions of a blockbuster drug varies, but they are generally broad-spectrum
drugs that treat large patient populations. See Perry, supra note 26, at 70; see also Mae
Thamer et al., A Cross-NationalComparison of Orphan Drug Policies: Implications for the
U.S. Orphan Drug Act, 23 J. HEALTH POL. POL'Y & L. 265, 270 (1998) (stating "[p]roposed
regulations for the FDA's generic drug program define blockbuster drugs as those with a
market above $50 million a year").
37. Lori B. Andrews, A Conceptual Framework for Genetic Policy: Comparing the
Medical, Public Health, and Fundamental Rights Models, 79 WASH. U. L.Q. 221, 258-67
(2001); Silver, supra note 18, at 17; Snedden, supra note 19, at 149. See generally Tara L.
Rachinsky, Genetic Testing: Toward a Comprehensive Policy to Prevent Genetic Discrimination in the Workplace, 2 U. PA. J. LAB. & EMP. L. 575 (2000) (discussing genetic discrimination in the workplace).
38. Snedden, supra note 19, at 145. For example, sickle cell disease is common among
those of African descent while cystic fibrosis often affects those of northern European
descent. STRUCTURES OF LIFE, supra note 20, at 6. Other examples of racial differences in
responses to chemicals include studies showing (1) the more pronounced effects of atro-
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zymes involved in the metabolism of alcohol, namely ADH (aldehyde
dehydrogenase) and ACDH (alcohol dehydrogenase) enzymes, are more
common in Asians, particularly in the Japanese.3 9 Hence, a difference 4in°
alcohol tolerance exists between Caucasian and Asian populations.
However, does the determination of traits like alcohol sensitivity contribute to the idea of genetic determinism and genetic discrimination? Although genes correlate to specific physiological functions, they do not
explain everything, because genes work in conjunction with environmental and behavioral factors. 4'
For example, recombinant DNA technology has allowed scientists to
trace human ancestry from the maternally inherited mitochondrial DNA
to the paternally inherited Y chromosome.42 The scientists' comparison
of present day populations confirms a common ancestry originating in
Africa and documents how the African gene pool had the most variation
in the world. 43 Additionally, scientists have discovered how individuals in
the same population, even in small or isolated areas, have a greater percentage of genetic variation than persons from different continents.4 4
Hence, individuals in homogenous groups, who possess superficially similar traits, are more different from each other than if genetically compared
with an individual outside their race.4 5 Yet, despite the discovery of a
common ancestry in Africa, individuals persist in using race and ethnicity
to differentiate human populations. 46 From the scientific perspective, the
stereotypical features associated with race merely reflect allelic combina-

pine among blacks than whites; (2) the more pronounced dilatory effects of cocaine and
pseudoephedrine on the eyes of Chinese and Caucasians than on blacks; and (3) the better
resistance by blacks to skin blistering from exposure to mustard gas than by whites.
Weber, supra note 5, at 142.
39. Medicine Made to Match, supra note 17, at 3; Snedden, supra note 19, at 156.
40. Medicine Made to Match, supra note 17, at 3; Snedden, supra note 19, at 156.
Although genes contribute to the variance in people's susceptibility to diseases, certain
genes can make people resistant or vulnerable to a disease. Peltonen & McKusick, supra
note 25, at 1226-27. The same variance can be said about people's response to medication.
A single gene, a compilation of genes, or a person's diet and environment may govern the
body's reaction. POWLEDGE, supra note 10, at 52. Pharmacogenomics will use the information from genome sequencing to predict how individuals respond to medications. Id.
41. Robbins-Roth, supra note 25, at 172; Wortman, supra note 17, at 72-75.
42. Kelly Owens & Mary-Claire King, Genomic Views of Human History, 286 Sci.
451, 451 (1999).
43. Id.; Svante P5iibo, The Human Genome and Our View of Ourselves, 291 SCI. 1219,
1219 (2001).
44. Owens & King, supra note 42, at 452 (stating the human genetic diversity among
individuals in different continents is 10% while the genetic variation is 80% among individuals in the same population); P55bo, supra note 43, at 1220.
45. Owens & King, supra note 42, at 453.
46. Paabo, supra note 43, at 1219.
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tions.4 7 Therefore, scientists hypothesize that since minute genetic mutations determine superficial traits, such as hair color, skin color, hair
texture, and facial traits, the environment (e.g., climate) is a reasonable
cause for the variation in those traits.4 8
Another argument parallels the following:
We've called the human genome the blueprint, the Holy Grail, all
sorts of things. It's a parts list. If I gave you the parts lists for the
Boeing 777 and it has 100,000 parts, I don't think you could screw
it
49
flew.
it
why
understand
wouldn't
certainly
you
and
together,
In other words, the Human Genome Project seeks to determine the
complete nucleotide sequence of the human genome - deciphering every
adenine (A), thymine (T), cytosine (C) and guanine (G). 5" Although
many of these nucleotide sequences consist of non-coding DNA,5 1 an understanding of the genome with these individual pieces of information
alone cannot be made without looking at the totality of the information.
This misunderstanding is further exacerbated by the misconstrued ideas
perpetuated by the media. For example, media fervor is given to scientific reports purporting to have discovered the "genes for" certain traits
such as aggression52 and homosexuality.5 3 These journalists, however,
only add to society's misconception of genetic information by incorrectly
suggesting the mere presence
of a gene corresponds to the manifestation
54
of a trait or disorder.

47. Id. at 1220.
48. Owens & King, supra note 42, at 453.
49. Timeline, supra note 11, at 1198 (quoting a portion of Eric Lander's address before
the Millennium Evening at the White House, (Oct. 14, 1999)).
50. Roberts, supra note 6, at 1183; Venter et. al., supra note 6, at 1305. Nucleotides
are the building blocks of RNA (ribonucleic acid) and DNA. They include a base (A, T, C,
or G - the written alphabet of the DNA code), a phosphate molecule, and a sugar molecule (ribose in RNA and deoxyribose in DNA). POWLEDGE, supra note 10, at 3.
51. Non-coding DNA consists of bases that do not code for genes. ROBERT F.
WEAVER & PHILIP W. HEDRICK, GENETICS 269-70 (2d ed. 1992); STEDMAN'S, supra note 3,
at 918; POWLEDGE, supra note 10, at 12; see also Gretchen Vogel, Objection #2: Why Sequence the Junk? 291 Sci. 1184, 1184 (2001) (explaining how the human genome has more
non-coding DNA than any other animal).
52. Peter McGuffin et al., Toward Behavioral Genomics, 291 Sci. 1232, 1232 (2001).
The behavioral trait of aggression has been identified in a mutation reported in the Xlinked MAO A gene. Id.
53. Id. Linkage has been reported at the X-linked marker locus on "sib pairs" for
male homosexuality. Id.
54. See id. Not all genes are "genetic" although genes are involved in all diseases.
POWLEDGE,

supra note 10, at 55. Diseases caused by single gene mutations are common.
43 (2002).

GREGORY STOCK, REDESIGNING HUMANS: OUR INEVITABLE GENETIC FUTURE

Examples of these single gene mutations include Lesch-Nyhan syndrome, which is an Xlinked inheritance that leads to mental retardation and self-mutilation of fingers and lips
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The misconception that harboring certain genes will manifest into specific traits or disorders leads people to fear third parties will abuse pub5
licly disseminated information obtained about an individual's genotype. 1
People fear employers, insurers, and schools may discriminate or stigmatize simply because a person carries traits linked to diseases. 56 However,
this type of discrimination has the similar invidious
effect of delegating
57
the person into a suspect classification, like sex.
If persons experiencing genetic discrimination are "suspect," then these
people carrying certain traits or disorders are afforded special protection.
But what is "suspect classification?" The Supreme Court of the United
States distinguishes suspect classification from non-suspect classification
by asking whether the trait bears any relation to the individual's ability to
"perform or contribute to society. "58 Take, for example, alcohol addiction. Although a person may have the propensity for this disease, a genetic predisposition to it does not necessarily determine whether or not
the individual will abuse alcohol. 59 Additionally, carriers of diseases, like
sickle cell anemia, do not necessarily develop the symptoms. 60 Hence,
the sequences of one's genes does not necessarily determine whether or
not the trait will be expressed.
This thought of genetic discrimination conjures up a myriad of other
issues. One such issue is eugenics, which carries the shadow of negative
eugenics from the Nazi racist genocide.6 1 Also under the umbrella of
eugenics is positive eugenics, or the power to reengineer the human speby biting; Tay-Sachs disease, which leads to early neural degeneration, then to a failure to
develop motor skills, and eventually to death; and Werner's syndrome, which manifests
premature aging. STEDMAN'S, supra note 3, at 521, 1939, 1771; STOCK, supra, at 43. However, a combination of genetic and environmental factors influence complex disorders such
as asthma, arthritis, most cancers, diabetes, heart disease, and mental disorders that are
common diseases killing millions of people. See POWLEDGE, supra note 10, at 55. See
generally Peltonen & McKusick, supra note 25 (comparing the genetic background of monogenic diseases and complex disorders).
55. See Mary Z. Pelias & Nathan J. Markward, The Human Genome Project and Public Perception:Truth and Consequences, 49 EMORY L.J. 837, 840-41 (2000) (highlighting the
factors contributing to the public perception of genetics as mysterious and threatening);
Smith & Burns, supra note 15, at 25 (concluding how advancements in DNA technology
and screening techniques create potential abuse by state and private entities).
56. See Pelias & Markward, supra note 55, at 840-41; Silver, supra note 18, at 17;
Smith & Burns, supra note 15, at 30.
57. See Smith & Burns, supra note 15, at 45, n.118.
58. Frontiero v. Richardson, 411 U.S. 677, 686-87 (1973); see Smith & Burns, supra
note 15, at 45.
59. See generally Silver, supra note 18 (disclosing the high likelihood of genetic discrimination despite the fact people can overcome their genetic instincts).
60. Smith & Burns, supra note 15, at 45 n.118.
61. Pelias & Markward, supra note 55, at 855-56.
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cies.6" Another issue is the determination of the genetically less fortunate. Who are these people facing discrimination simply because they
carry a gene expressing a certain trait or disorder and are thus labeled the
"genetically less fortunate?" Existing legislation uses broad sweeping

language to define terms such as genetic discrimination and genetic information. Are these terms to include minorities, indigenous peoples, the
disabled, the cosmetically imperfect, or the diseased?6 3

Also, one must consider whether the history of scientific discrimination
against minority populations in the United States, like the sterilization

laws at the turn of the twentieth century,6 4 may discourage minorities

from taking advantage of the benefits offered by pharmacogenomics
Finally, as the ideas of pharmacogenomics solidify, how will it affect current legislation?6 6
As a new field in biotechnology, pharmacogenomics shares similar social, ethical, medical, and legal concerns related to genetic research. The
valuable knowledge and the possible benefits to humanity this field offers
keeps pharmacogenomics in the forefront of biotechnology. Yet the
pharmaceutical industry and governments are left to resolve issues arising
out of people's ethical, legal, medical, and social concerns.

62. See id. at 855-56 (explaining positive eugenics encourage the propagation of survival of the fittest).
63. See generally Andrews, supra note 37 (exploring how third parties could use a
person's genetic information to stigmatize and discriminate against them); Smith & Burns,
supranote 15, at 35 (describing potential forms of discrimination); Henry T. Greely, Genotype Discrimination: The Complex Case for Some legislative Protection, 149 U. PA. L. REV.
1483 (2001) (providing an overview of genetic discrimination and the protections afforded
under present statutes).
64. Rifkin, supra note 9, at 122. At the beginning of the Twentieth Century, various
state laws involuntarily sterilized thousands of American citizens. Id. "Confirmed
criminals, idiots, imbeciles, and others in state institutions" were manditorially sterilized in
order to "weed out the biologically inferior stock" from America. Id.
65. See generally Andrews, supra note 37 (recognizing the potential abuses of genetic
information).
66. Take, for example, the Orphan Drug Act. Orphan Drug Act, 21 U.S.C. §§ 360aa360ee (2001); see also Gary A. Pulsinelli, The Orphan Drug Act: What's Right With It, 15
SANTA CLARA COMPUTER & HIGH TECH. L.J. 299, 300 (1999) (discussing the history, provisions, and amendments of the Orphan Drug Act). The Orphan Drug Act encourages
pharmaceutical companies to develop products for orphan diseases, which affect less than
200,000 persons in the United States. 21 U.S.C. §§ 360aa-360ee; see also Snedden, supra
note 19, at 150 (stating the U.S. Food and Drug Administration created the orphan status conditions or diseases "afflicting fewer than 200,000 people" - through the Orphan Drug
Act to encourage drug pharmaceutical companies to develop drugs for rare diseases); Mignon Fogarty, Up for Adoption: Pharmacogenomics and the Orphan Drug Law, (Biomednet Dec. 11, 1998), available at http://www.pst.fhg.de/pla/german/info/news/archiv/
10021.htm (last visited Feb. 7, 2003).
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HISTORICAL PERSPECTIVE: AN INTRODUCTION
TO PHARMACOGENOMICS

"My doctors are claiming that my humanity, my genetic essence, is
their invention and theirproperty. They view me as mine from which
to extract biological material. I was harvested."67
-John

Moore

The social and legal issues in pharmacogenomics parallel those found
in other fields of genetic engineering, such as cloning,68 stem cell research,69 and gene therapy. 70 The root of these issues originates from the
genetic information obtained. Its offshoots are people's fears of potential
discrimination and the embroilment into privacy issues. These issues also
impact the social areas of employment, insurance, and education and the
legal concepts of constitutional rights,71 property rights,72 and privacy

67. Lore ANDREWS, THE CLONE AGE 191 (1999) (quoting Moore's reaction to his
doctors' actions). In 1976, John Moore sought treatment at the Medical Center of the
University of California at Los Angeles for hairy-cell leukemia. Moore v. Regents of Univ.
of Cal., 793 P.2d 479, 480-81 (Cal. 1990); ANDREWS, supra, at 191. The doctors, aware of
the scientific and commercial value of Moore's cells, removed his spleen. Moore, 793 P.2d
at 481; ANDREWS, supra, at 191. After the splenectomy, they retained Moore's spleen for
research purposes: they established a cell line, which they patented, from Moore's cell and
earned millions of dollars selling the rights to a biotech company without Moore's consent.
Moore, 793 P.2d at 481-82; ANDREWS, supra, at 191. Moore sued for wrongful conversion
alleging his blood and bodily substances were his tangible and personal property - that he
owned his body, his tissues, and his own DNA. Moore, 793 P.2d at 482; ANDREWS, supra,
at 191. However, the California Supreme Court disagreed. See generally Moore, 793 P.2d
479 (concluding although the actions against Moore were unethical, they are not illegal).
The Court held patients must be informed in advance if their tissues are to be used for
commercial products or research but denied Moore's claim of property rights over his own
body. Id.; ANDREWS, supra, at 192.

68. See e.g., Rifkin, supra note 9, at 110-13 (lamenting the loss of genetic diversity,
especially in plants, when replicating and mass producing hardy genes); STOCK, supra note
54, at 139-40 (addressing fears such as impoverished genetic constitutions with the diminished biological diversity and viewing cloned individuals as objects not as human beings).
69. See e.g., STOCK, supra note 54, at 130-39, 161-65 (discussing how the divisiveness
of playing God by enhancing human vulnerability and extending life spans engenders anxiety in many people).
70. See e.g., id. at 235 n.146 (providing an example of genetic discrimination in the
workplace wherein the employer fired an employee for accumulating high medical expenses while undergoing preventative therapy treatments for Alpha-i, a genetic
condition).
71. See generally John B. Attanasio, Science Tests Human Dignity: The Challenges of
Genetic Engineering, 53 SMU L. REV. 455 (2000) (presenting constitutional concepts with
regards to genetic engineering); Smith & Burns, supra note 15, at 43, 50 (discussing
whether genetic discrimination will create a suspect class and whether genetic screening
constitutes unreasonable searches and seizures).
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rights.7 3 What makes pharmacogenomics unique is its use of individuals'
genetic makeup to create drugs specifically designed to their genetic tendencies in order to better combat diseases;74 whereas other genomic
fields 75 target a specific gene to inhibit or reduce the disease and its consequences or to over-express a gene that would combat the disease.7 6
Since pharmacogenomics seeks to move away from the broad spectrum
approach of drug manufacturing toward a narrower spectrum, these designer drugs require the targeting of specific patient subpopulations.7 7
Yet, before a discussion on how focusing on the disease, not the patient,

72. See generally Moore, 793 P.2d 479 (rejecting plaintiff's claim that his body tissues,
cells, and DNA were his property); D.M., Will a Smaller Genome Complicate the Patent
Chase?, 291 Sci. 1194, 1194 (2001) (explaining how commercialization of the gene has led
to patent fights).
73. Karen Rothenberg et al., Genetic Information and the Workplace: Legislative Approaches and Policy Challenges, 275 Sci. 1755, 1755 (1997).
74. Paul Smaglik, PharmacogeneticsInitiative Galvanizes Public and Private Sectors,
410 NATURE 393, 393 (2001) (stating the aims of pharmacogenomics is to tailor drug prescriptions to each patient).
75. See generally Katheryn D. Katz, The Clonal Child: ProcreativeLiberty and Asexual Reproduction, 8 ALB. L.J. Sci. & TECH. 1 (1997) (discussing the legal implications in
creating a cloned human); Gerald Coleman, Comment, Genetic Engineering: Should Parents Be Allowed to Design Their Children?, 34 How. L.J. 153 (1991) (describing the issues
inherent in designing children).
76. Despite the conserved sequence of DNA that connects all of humanity, each individual has a unique genetic makeup that is a result of the combination of parental genes
and normal nonlethal mutations occurring at the genetic level. See generally POWLEDGE,
supra note 10 (explaining the science of genetics). This concept defines the uniqueness of
pharmacogenomics, whereby drugs are specifically designed to an individual's genetic tendencies. Such an idea is of great importance to both the medical and scientific community,
because patient responses to diseases differ on a molecular level. That is, variations in
genetic expression and protein interactions affect the binding efficiencies of drugs. See
generally William A. Haseltine, Discovering Genes for New Medicines, 276 Sci. AM. 92
(1997) (explaining gene expression in diseases). In contrast, other genomic fields counteract diseases by combating common motifs present in DNA. That is, certain gene domains
common to humanity are targeted with drugs that could either inhibit lethal gene expressions or induce the overexpression of chemopreventive genes. See generally French W.
Anderson, Gene Therapy, 273 Sci. AM. . 124 (1995) (explaining how gene therapy works:
by transporting genetic material into the patient either by inserting "a healthy copy of a
gene into the... [cell] in order to compensate for a defective gene" or to purposely alter a
gene); Matthew J. Plunkett & Jonathan A. Ellman, Combinatorial Chemistry and New
Drugs, 276 ScI. AM. 68 (1997) (discussing the process of combinatorial chemistry wherein
compounds are screened for medicinal value); Robert Tijan, Molecular Machines that Control Genes, 272 Sci. AM. 54 (1995) (noting how current knowledge of gene regulation can
lead to the development of drugs that combat life-threatening diseases by blocking gene
expression).
77. WEAVER & HEDRICK, supra note 51, at 578; McCarthy, supra note 32, at 27; The
Right Medicine, supra note 34, at 3.
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can create a conglomerate of social and legal concerns, a look into human
history and the genome must first be presented.
A.

The Genome and Human History

Genetics has the power to reveal the past. For example, mitochondrial
DNA (mtDNA) is generally maternally inherited with virtually little recombination between mitochondria. 78 Thus, the assumption is that a
common female ancestor exists among individuals with the same type of
mtDNA. Also, the Y-chromosome, which is purely paternally inherited,
has no recombination on the chromosome's Y-specific region.7 9 Yet, like
mtDNA, the Y-chromosome offers a gender-specific record of the past."°
Phylogenetic techniques 8 in human mtDNA suggest current mtDNA,
and therefore humans, descended from a female originating out of Africa
some 200,000 years ago.8 2 Further analysis shows the African gene pool
having more genetic variation than the gene pool outside Africa.83 Additionally, a greater genetic diversity exists among individuals in the same
population rather than among individuals from different continents.8 4 A
78. WEAVER & HEDRICK, supra note 51, at 578; Owens & King, supra note 42, at 451;
see also BRYAN SYKES, THE SEVEN DAUGHTERS OF EVE 54 (2001) (explaining how

mtDNA is maternally inherited).
79. WEAVER & HEDRICK, supra note 51, at 53; Owens & King, supra note 42, at 451.
80. SYKES, supra note 78, at 194 (explaining how mtDNA and the Y chromosome told
the same gender specific story of the past).
81. A "phenotype" is the "morphological, biochemical, behavioral, or other properties of an organism." WEAVER & HEDRICK, supra note 51, at 633. A "genotype," on the
other hand, is the "allelic constitution of a given individual." Id. at 628. In other words,
the phenotype is the observable characteristics and the genotype is the genetic characteristics. The differences among related species can be measured through these phenotypic and
genotypic traits. Using this information, scientists arrange these groups of related populations or species to illustrate ancestral relationships. Scientists use diagrams called phylogenetic trees to show these relationships. WEAVER & HEDRICK, supra note 51, at 577.

Therefore, phylogenetic techniques are the methods used to create this biological relationship. Cf SYKES, supra note 78, at 277 (claiming "genetics tells us very clearly that modern
humans had their origins in Africa within the last hundred and fifty thousand years).
82. WEAVER & HEDRICK, supra note 51, at 578;

ALDRIDGE,

supra note 10, at 17. See

generally Paiibo, supra note 43 (elucidating how humans are from a global family with
common ancestry); Owens & King, supra note 42 (explaining how genomic technology can
shed light to history). The tools of genomic analysis have shed light on human history
through the analysis of the written record encoded in the DNA. Id. at 451. The few genes
with the ability to encode visible traits and the Y chromosomal DNA and mitochondrial
DNA all have unique inheritance patterns that scientists can use to trace a particular
human population back to a common ancestor. Paabo, supra note 43, at 1220. Scientists
used current mitochondrial DNA to trace a back to female some 200,000 years ago.
WEAVER & HEDRICK, supra note 51, at 578.

83. Paitbo, supra note 43, at 1219; Owens & King, supra note 42, at 452.
84. Owens & King, supra note 42, at 453.
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possible explanation of mtDNA migration is females historically have a
higher migration rate than males.8 1 They tend to relocate to their husbands' birthplace and give birth to their children there.8 6
The possibility humans migrated out of Africa belies humanity's concept of race - that each individual belongs to a particular homogenous
group. The stereotypical features of race (e.g., skin and hair color) are
superficial, because they merely affect the body's exterior and do not indicate other variations within the genome, and are environmentally influenced (e.g., climate affecting skin pigmentation).8 " This genetic
perspective of individuals from different races being more related to each
other than to persons of the same race shatters the practice of racial classification. If anything, knowledge of the genome should foster compassion. With a mixed gene pool and with everyone carrying at least some
deleterious alleles, stigmatizing a particular group based on one's allele is
ludicrous.8 8 Yet, ethnicity remains a major force in society. The genetic
analysis of human populations and the resulting information can lead to
abuse.
B.

Genetic Determinism and Discrimination

Genotyping racial and ethnic groups can backlash because many diseases are racially and ethnically related.8 9 For example, Jews are common carriers of Tay-Sachs and Gaucher's disease, 90 Armenians are more
prone to Familial Mediterranean Fever disease, and Africans are common carriers of the sickle-cell anemia trait.91
85. Id. at 451.
86. Id.
87. Paabo, supra note 43, at 1220; Owens & King, supra note 42, at 453.
88. P55bo, supra note 43, at 1220.
89. Examples of ethnically related diseases include asthma (among the isolated people of Easter Island, the Brazilian Highlands, and Tristan da Cunha, scientists have found
susceptibility genes); Huntington's Disease (prevalent in an island in Venezuela), diabetes
(prevalent in Nigeria, Ghana, and among the Pima Indians in Arizona), Alzheimer's (the
Cherokee of Oklahoma seem resistant to Alzheimer's), and HTLV, a leukemia-causing
virus (the Hagahai of New Guinea are resistant to a leukemia-causing virus, HTLV).
Nelkin, supra note 3, at 126.
90. Id. Tay-Sachs and Gaucher are lysosomal storage diseases. STEDMAN'S, supra
note 3, at 515, 521. Tay-Sachs can cause a failure in infants to develop motor skills. Id. at
521. In the first year, blindness and seizures are evident; within a few years, death occurs.
Id. Gaucher, on the other hand, is commonly found among people of Ashkenazi Jewish
descent. Id. at 515. It occurs most severely in infants with characteristics including bone
lesions, seizures, and dementia. Id.
91. Nelkin, supra note 3, at 126; RIFKIN, supra note 9, at 163. Sickle cell results in
abnormal red blood cells, "which appear in response to a lowering of the partial pressure
of oxygen," and is characterized by such manifestations as anemia and chronic leg ulcers
and bone deformities. STEDMAN'S, supra note 3, at 521. In the 1970s, when scientists
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Although DNA sequences supply the instructions to construct a living
organism, this "blueprint" does not foretell the organism's success in
life,92 because epigenetic mechanisms will also exert their influence on it.
Yet, belief in biological and genetic determinism still exists. These concepts suggest genetics or biology predetermines one's fate.93 Such ideologies have led to many incidents of positive and negative eugenics around
the world.
C. The Shadow of Eugenics
"If we could make better humans... why shouldn't we?"9 4

-James

Watson, Scientist

Sir Francis Galton9 5 coined the term "eugenics," which is the process
whereby desirable traits in the human gene pool are selected and undesirable traits are eliminated.96 Positive eugenics involves improving the
characteristics of a species or an organism.97 The current use of genetics

discovered the sickle-cell anemia trait, many African Americans, specifically carriers of the
recessive gene, experienced employment discrimination. RIFKIN, supra note 9, at 164; see,
e.g., Nelkin, supra note 3, at 130 (describing how eight African American employees of the
Lawrence Berkeley Laboratory at the University of California were tested, without their
knowledge or consent, for the sickle cell mutation). The United States Air Force Academy
denied entrance to these carriers under the mistaken belief they would not function in
oxygen-reduced environments, because the affected gene was for the blood's oxygen carrying red blood cells, which they assumed would sickle at high atmospheric levels. JERRY E.
BISHOP & MICHAEL WALDHOLZ, GENOME 299 (1999) (stating the ban on sickle cell carriers was eventually lifted following medical and public protests of racism); RIFKIN, supra
note 9, at 164 (claiming other carriers were denied jobs in the chemistry industry in toxic
sensitive environments).
92. Barbara R. Jasny & Pamela J. Hines, Genome Prospecting, 286 ScI. 443, 443
(1999).
93. Colin S. Diver & Jane Maslow Cohen, Genophobia: What is Wrong With Genetic
Determinism?, 149 U. PA. L. REV. 1439, 1448 (2001).

94.

STOCK,

supra note 54, at 12.

95. Sir Francis Galton, the cousin of the English biologist and evolutionist Charles
Darwin, was also an English scientist. STEDMAN'S, supra note 3, at 459, 724; see also

Eugenics, in

GALE ENCYCLOPEDIA OF PSYCHOLOGY

(2d ed. 2001) available at http://

www.findarticles.com/g2699/0001/2699000124/pl/article.jhtml (last visited Oct. 31, 2002).
He is known as the founder of eugenics. Leslie Jones, Social Darwinism Revisited, HisTORY TODAY (August 1998), available at FindArticles.com, http://www.findarticles.com/
m1373/n8_v48/21031902/pl/article.jhtml (last visited Oct. 31, 2002).
96. Lisa Sowle Cahill, Genetics, Ethics and Social Policy: The State of the Question, in
THE ETHICS OF GENETIC ENGINEERING,

Cahill, eds., 1998);

97.

RIFKIN,

at vii, vii (Maureen Junker-Kenny & Lisa Sowle

supra note 9, at 116; Smith & Burns, supra note 15, at 24 n.9.
supra note 9, at 116; Smith & Burns, supra note 15, at 25 n.9.
RIFKIN,
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tests, 9 8 via gene therapy, to apply the information obtained from the
Human Genome Project is an example of positive eugenics. Negative
eugenics, on the other hand, systematically eliminates undesirable biological traits in organisms or species.9 9 Sterilization efforts, selective mating,
and the detection and subsequent elimination of "defective" fetuses or
embryos are applications of negative eugenics.10 0
During the eugenics movement of the Nazi regime in Germany, religion, ethnicity, and sexual orientation were traits used to identify undesirables.' 0 1 The United States also had its own eugenic past. From the
turn of the 1900s until the Great Depression, a number of the American
intellectual elite and some people of the white Anglo-Saxon race embraced eugenic ideology. 10 2 The movement itself was spawned during the
first massive wave of immigration into the United States in the 1890s and
the growth of inner-city slums.10 3 Eugenics reached a peak during World
War I with the red scare as some of the white Anglo-Saxon elite became
paranoid of losing their social and economic status. 0 4
The idea that heredity, not the environment, determines individuals'
behaviors and status in society attracted some of the white Anglo-Saxon
elite.105 Thus, they turned to eugenics. Even Alexander Graham Bell
stated: "We have learned to apply the laws of heredity so as to modify
and improve our breeds of domestic animals. Can the knowledge and
experience so gained be available to man, so as to enable him to improve

98. Genetic tests are being developed for diseases that include cystic fibrosis, breast
cancer, colon cancer, Huntington's disease, Tay-Sachs, Duchenne muscular dystrophy,
Gaucher, hemophilia, fragile X syndrome, and sickle cell anemia. Edward S. Colub, Ethical ConsiderationsArising From Economic Aspects of Human Genetics, inCHANGING NATURE'S COURSE: THE ETHICAL CHALLENGE OF BIOTECHNOLOGY

78 (Gerhold K. Becker

& James P. Buchanan, eds., 1996); Eliot Marshall, The Genome Program'sConscience, 274
ScI. 448, 448 (1996).

99. RIFKIN, supra note 9, at 116; Smith & Burns, supra note 15, at 24 n.9.
100. Cahill, supra note 96, at vii.
101. Smith & Burns, supra note 15, at 25 n.9.
102. RIFKIN, supra note 9, at 118.
103. Id. Moral, racial, and social issues influenced the American eugenics movement.
Eugenics, supra note 95; see also Nelkin, supra note 3, at 123 (explaining how immigration
authorities argue the "Mediterranean races were intellectually inferior to the Nordic race"
because of "their propensity for degeneracy, crime, and congenitally poor health").
104. RIFKIN, supra note 9, at 118.
105. Id. For example, one of America's foremost geneticist, Charles Davenport,
played an active role in the Eugenics movement. Stephen Jay Gould, The International
Brand of the Scarlet (Genetic Aspects of Nomadism), NATURAL HISTORY (Mar. 1998),
available at http://www.findarticles.com/ml134/n2_vlO7/20485353/pl/article.jhtml (last visited Feb. 7, 2003).
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the species to which he himself belongs?"'0 6 Margaret Sanger, the wellknown feminist who fought for birth control programs, also subscribed to
the notion that biology influenced the superiority or inferiority among
different groups.' 7 This belief led to the formation of a significant
amount of eugenic societies.' °8 They included the American Breeders
Association, which set up the first functioning Committee on Eugenics in
1906, and the formation of the Eugenics Committee of the United States
in 1922, later renamed the American Eugenics Society.' °9
The United States applied these eugenic concepts in the form of sterilization laws as a tool for weeding out the biologically inferior." 0 In 1907,
111
Indiana became the first state to pass a mandatory sterilization law.
Other states passed similar laws in which "confirmed criminals, idiots,
imbeciles, and others in state institutions" were manditorially sterilized in
12
order to "weed out the biologically inferior stock" from America.'
13
However, most of these state laws have since been overturned.

106. Bell gave this speech before the American Breeders Association in Washington
in 1908. RIFKIN, supra note 9, at 121. Contra STOCK, supra note 54, at 151 (quoting one
contemporary view regarding eugenics: "Positive eugenics, any tailoring of an individual's
genetic endowment... will put us on a slippery slope to the abolition of man").
107. RIFKIN, supra note 9, at 121.
108. Id. at 119-20.
109. Other eugenics societies in the United States include: The Eugenics Record Office in Cold Spring Harbor, New York, established in 1910, The Galton Society of New
York, established after 1910, and The Eugenics Association, formed in 1913. Id.
110. Id. at 122. The eugenics movement in the United States disproportionately institutionalized and sterilized more women than men. ANDREWS, supra note at 67, at 131. In
general, victims included people diagnosed with deafness, epilepsy, mental retardation, and
psychiatric symptoms. Eugenics, supra note 95. They were also people of "low moral stature." Id. These people included prostitutes, thieves, and unwed mothers. Id; see also
Nelkin, supra note 3, at 123 (noting how eugenicists claimed "intelligence, feeblemindedness, special talents, criminal tendencies, industriousness, pauperism, alcoholism, laziness,
poverty, loquacity, harlotry, and vagrancy were all heritable traits distinguishing certain
families and groups").
111. RIFKIN, supra note 9, at 122; see Eugenics, supra note 95. But see Smith & Burns,
supra note 15, at 25 n.9 (noting how most states' sterilization laws have been overturned).
112. RIFKIN, supra note 9, at 122. Thirty states, between 1907 and 1931, passed sterilization legislation for people considered "feebleminded" or who have criminal tendencies.
ANDREWS, supra note at 67, at 131. They were informally called "Mississippi appendectomy[ies]," because the recipients were often poor individuals from the South. Id. Over
64,000 people received these "appendectomies." Id. Some were performed without the
people's knowledge or against their will. Id. Legislators also created miscegenation laws
to prevent interracial marriages. Eugenics, supra note 95. These compulsory sterilization
laws reflected the belief that undesirable traits would proliferate in the dominant populace
if individuals of different races were allowed to mix. Id.
113. E.g., McKinney v. McKinney, 805 S.W.2d 66, 69 (Ark. 1991) (holding unconstitutional Arkansas's involuntary sterilization laws on mental incompetents because it did not
provide sufficient procedural protection); Skinner v. Oklahoma, 316 U.S. 535 (1942) (strik-
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The decline in the eugenics movement in the United States occurred
after 1924.'14 It met its death with the collapse of the stock market and
Hitler's rise to power in 1929.15 Once Hitler's Third Reich came into
power in 1933, the Germans established the Hereditary Health Law1 16 as
a eugenic sterilization statute. 117 The statute became the first step in the
Nazi's mass eugenic program. Scandinavian countries, like Sweden, also
had their own eugenic programs. Sweden's sterilization law, which was
abolished in 1976, forcibly denied about 100,000 women the right to
reproduce.' 1 8 With the new genetic engineering tools having the potential to reengineer man's blueprint, they evoke the specter of these negative eugenics past.
D.

The Nature of Pharmacogenomics

Nonetheless, pharmacogenomics proposes to elucidate the differences
in drug responses by focusing on genetic polymorphisms of drugs metabolizing enzymes.' 9 Studies to date show these polymorphisms differ in
frequency amid ethnic and racial groups. 2 ° Take, for example, MC1R, a
melanocortin-stimulating hormone receptor gene, which may cause the
variations in skin and hair color. 121 Although not a pharmacogenetic polymorphism, it illustrates the relationship between ethnicity and genetics.
The amount of melanin, emalanin (brown and black melanins that provide protection against ultraviolet (UV) radiation) and phaeomelanin
(red and yellow melanins that may contribute to UV induced skin damage), vary to cause these differences in color. 122 Variations in multiple
sites of the MC1R protein are found in over eighty percent of red-headed
individuals with fair skin that burns, not tans, and in less than four pering down the Oklahoma Habitual Criminal Sterilization Act, Okla. Stat. Ann. Tit. 57, § 171

et seq., an involuntary sexual sterilization law for repeat offenders). But see Buck v. Bell,
274 U.S. 200 (1927) (setting the precedent for sterilization of the "feebleminded" by upholding the Virginia Sterilization Act ch. 394 (1924)). Approximately 20,000 people were
sterilized by the end of the America's eugenics movement. Eugenics, supra note 95.

114. RIFKIN, supra note 9, at 125.
115. Id. at 125-26.

116. THE AMERICAN-ISRAELI COOPERATIVE ENTERPRISE, THE JEWISH VIRTUAL LI.
BRARY, LAW FOR THE PROTECTION OF HEREDITARY HEALTH: THE ATtEMPT TO IMPROVE
THE GERMAN ARYAN BREED (JULY 14, 1933), available at http://www.us-israel.org/jsource/
Holocaust/nurmlawl.html (2001) (last visited Feb. 7, 2003).

117. RIFKIN, supra note 9, at 126-27; Sandro Spinsanti, Gene Therapy and The Improvement of Human Nature: Ethical Questions, in THE ETHICS OF GENETIC ENGINEERING
14 (Maureen Junker-Kenny & Lisa Sowle Cahill, eds., 1998).
118. Spinsanti, supra note 117, at 14.
119. Evans & Relling, supra note 32, at 487.
120. Id. at 488.
121. Id. at 453.
122. Owens & King, supra note 42, at 453.
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cent of British or Irish individuals having skin that tans without burn124
ing.123 However, no variations were found among African individuals.
25
Among Asians, amino acid substitutions are common in MC1R.

With the marked diversity in pharmacogenetic polymorphisms, frequency of polymorphisms among racial and ethnic groups dictates the
aim of pharmacogenomics: to discover genetic or phenotypic associations
to diseases or drug toxicity, race must be considered.' 26 By targeting and

studying genetic subpopulations, pharmaceuticals can help diagnose dis-

127
eases and prescribe drugs according to their distinct biological makeup.

Despite this seemingly good news, a cloud of "genetic hypochondria"
1 28
lurks in the background.
PART

A.

III:

ANALYSIS

Genetics and the Law

Genes, generally those located on enzymes metabolizing drugs in the
liver, intestine, and other organs, are known to influence an individual's
reaction to specific drugs.' 29 Many of these drug-metabolizing enzymes

123. Id. Variation in the sequence of amino acids occurs in the second transmembrane domain, the first extracellular domain, and the seventh transmembrane domain. Id.
124. Id. at 453.
125. Id.
126. Evans & Relling, supra note 32, at 488.
127. Collaboration Works on Cancer Pharmacogenomics, CANCER WKLY., Mar. 21,
2000 (LEXIS, Sci. & Tech., Medical & Healthcare); see Jasny & Hines, supra note 92, at
443 (1999); Perry, supra note 26, at 70; The Right Medicine, supra note 34, at 3. Studies on
genetic variations in drug responses based on ethnicity, race, and gender have been conducted. Mark A. Rothstein, Abstract, Pharmacogenomics and Minority Populations,
NAT'L. INST. OF GEN. MED. ScI. (2001), available at http://www.nigms.nih.gov/pharmaco
genetics/#ethicalstudies (last visited Nov. 22, 2002). For example, studies on drug reactions by Native Americans are currently underway. Paul G. Spicer, Abstract, The
Promises and Pitfalls of Native Genetic Research, NAT'L. INST. OF GEN. MED. SCI. (2001),
available at http://www.nigms.nih.gov/pharmacogenetics/index.html (last visited Dec. 20,
2002).
128. P55bo, supra note 43, at 1220.
129. Brian Spear, Pharmacogenomics: Today, Tomorrow, and Beyond, 11(2) DRUG
BENEFIT TRENDS 53-54 (1999) (access to this article may be obtained through free registration at the Medscape website; on file with author), available at http://www.medscape.com
(last visited Feb. 7, 2003). Known drug metabolizing enzymes include CYP2D6, which
metabolizes many drugs including tricyclic antidepressants, a number of antiarrhythmics,
beta-blockers, and neuroleptics; TPMT, which metabolizes azathioprine, a drug that treats
leukemia and autoimmune disorders; and CYO2C19, which contributes to the metabolism
of anxiolytics and antiulcer medications. Becker, supra note 32, at 24; Peter L. Bullock,
Pharmacogenetics and Its Impact on Drug Development, 11(1) DRUG BENEFIT TRENDS 5354 (1999) (access to this article may be obtained through free registration at the Medscape
website; on file with author), available at http://www.medscape.com (last visited Feb. 7,
2003); Spear, supra note 129, at 53-54.
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exhibit polymorphic expression 130 that causes adverse drug reactions.
The idea that genetic variations in drug-metabolizing enzymes in the liver
may cause certain adverse drug reactions first came about in 1957.131
Two years later, in 1959, the term "pharmacogenomics" was used to de1 32
scribe this relationship between drug therapy and genetic makeup.
The science of pharmacogenomics came about in 1997 as a by-product
of the Human Genome Project.' 33 Ideas as to how pharmaceuticals could
enter the arena of personalized medicine followed. These ideas included
obtaining a list from doctors of patients suffering from adverse drug reaction to certain medications and contacting those patients to participate in
research studies or identifying the problems in the protein pathways causing the adverse drug reactions through the use of single nucleotide
13
polymorphisms (SNPs). 1
135
Despite the potential benefits pharmacogenomic studies may offer,
there are risks inherent with this biotechnology breakthrough.136 Studies
assessing the drug responses among individuals of different genotypes
and the relevant prevalence of genotypes in populations and subpopulations will reflect how certain traits are linked to ethnicity and gender,
while the degree to which other factors (e.g., environmental) interact with

130. Polymorphism causes the variability in DNA expression. It is a region of DNA
containing a difference or change in the base sequence from one individual to another.
When these polymorphisms occur in a gene, they may contribute to the difference in the
gene's protein product, which may give rise to the disease. See OXAGEN LTD. -GLOSSARY
OF TERMS, at http://www.oxagen.co.uk/pages/media-investors/6/index.html (last visited
Feb. 7, 2003).
131. Bullock, supra note 129, at 53-54.
132. Id.
133. Juan C. Mendible, Pharmacogenomics:Medicines Tailored Just for You (Jan. 3,
2000), at http://www.suite101.com/article.cfm/4866/31171 (last visited Feb. 7, 2003).
134. Id. If the SNP is within a gene, it may indicate the disease and the protein it
codes for by marking the location of the gene. Id.
135. Spear, supra note 129, at 53-54. Potential benefits in pharmacogenomics include:
(1) the ability to predict adverse drug reaction, (2) the distribution of proper medication
dosages, (3) the ability of patients to get well sooner since the optimal drug will be prescribed at the onset of the therapy, (4) decreased medical costs, and (5) increased understanding of the nature of important diseases, which will lead to new cures. See id.; Muin J.
Khoury & Jill Morris, Pharmacogenomicsand Public Health: The Promise of TargetedDisease Prevention, CENTER FOR DISEASE CONTROL, at http://www.cdc.gov/genomics/info/
factshts/pharmacofs.htm (last visited Feb. 7, 2003).
136. Potential risks in pharmacogenomics include misuse of the genetic information
and premature and indiscriminate application of the information. See Bullock, supra note
129, at 53-54.
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genetic factors to influence drug response will focus on individuals' economic status and geographic locale.' 37
Pharmacogenomics studies genetically inherited conditions by focusing
largely on genetic polymorphisms in drug metabolizing enzymes 13 8 in order to understand the differences in drug effects.' 3 9 Yet, the requirement
for homogenous samples in studies and the fact that many diseases are
gender- 40 and race- 41 based create a genetic profiling that has a potential for misuse, primarily in the insurance and employment arena.
Genetic testing does not guarantee a disease will manifest. Rather, it
indicates the likelihood of an individual's susceptibility to a particular disease. 142 The culmination of other factors, not just the mere possession1 of
43
a gene, influences the disease in its severity, onset, and manifestation.
This lack of understanding that a positive identification for a gene does
not necessarily equate to the manifestation of a disease may result in in-

137. Khoury & Morris, supra note 135. See generally Peltonen & McKusick, supra
note 25, at 1226 (comparing the genetic background of monogenic diseases and complex
disorders).
138. Genes exhibiting genetic polymorphism include dihydropyrimidine
dehydrogenase, which is linked to flourouracil neurotoxicity, and thiopurine methyltransferase, which is linked to thiopurine toxicity and efficacy and which increases the risk for
second cancers. Evans & Relling, supra note 32, at 489 (providing a comprehensive list of
genetic polymorphisms influencing drug metabolism).
139. Evans & Relling, supra note 32, at 487.
140. Examples of gender-based diseases include those affecting women: Rheumatoid
arthritis affects 1.5 million American women. PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, SELECTED MEDICINES IN DEVELOPMENT FOR WOMEN, at http://
www.phrma.org/publications/quickfacts/19.11.2001.312.cfm (last visited Feb. 7, 2003). This
year approximately 175,000 new cases of breast cancer will be diagnosed. Id. Ovarian
cancer, the "silent killer," will kill more than 14,000 American women this year. Id.
Alzheimer's disease kills twice as many women than men. Id.
141. Race based diseases exist for many ethnicities. Take for example the African
American population: The death rate for heart disease is higher among African Americans
than Caucasians. PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, SELECTED MEDICINES IN DEVELOPMENT FOR MAJOR DISEASES AFFECTING AFRICAN AMERI-

at http://www.phrma.org/publications/quickfacts/13.09.2002.548.cfm (last visited Feb.
7, 2003). Since the 1960s, the number of African Americans with diabetes has tripled. Id.
Glaucoma occurs six to eight times more often among African Americans than among
Caucasians. Id. African Americans have a 30% greater chance of dying from cancer than
Caucasians. Id.
142. Kyle G. French, Note, The Elderly and the Discriminatory Use of Genetic Information, 5 ELDER L.J. 147, 155 (1997); Paul Steven Miller, Is There a Pink Slip in My
Genes? Genetic Discriminationin the Workplace, 3 J. HEALTH CARE L. & POL'Y 225, 231
(2000).
143. Miller, supra note 142, at 231-32; e.g., BISHOP & WALDHOLZ, supra note 91, at
283 (explaining how prenatal tests for diseases, where the victim lives a long but disabled
life, detect the presence of the mutation but does not determine the severity of the
disease).
CANS,
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surer and employer misinterpretation and misuse of genetic information
as well as in people's refusal
to take genetic tests for fear of reprisal by
14
employers or insurers.1
Although pharmacogenomics examines individuals already exhibiting
symptoms of their diseases in order to rectify or ease their conditions,
pharmacogenomics also concerns the prevention of diseases (e.g., vaccinations). This framework may appear beneficial and may lack any basis
for discrimination by the employer, insurer, and the individual, but the
1 45
mere fact a genetic profile exists contravenes that idea.
1. State Legislation
"[W]ith genetic tests, insurance companies can virtually eliminate the
guesswork in underwriting. They can seek out people who are genetically pure, creating a ghetto of the uninsured, because they will know
146
who is likely to get a particulardisease at a particularage. ,
-J.

Brian McCall

The fear that one's genetic profile may be misinterpreted and misused
resulted in a flurry of legal protection for genetic privacy. 147 The scope
and content of resulting legislative acts vary; however, they tend to imple148
ment restrictions on the disclosure or use of genetic information.
While disclosure restrictions generally forbid the release or communication of genetic information without an individual's prior consent to third
144. Miller, supra note 142, at 232; cf. BISHOP & WALDHOLZ, supra note 91, at 282
(relating an example of one insurer who agreed to pay for a couple's prenatal test but
would subsequently require the parents to abort the child if it was affected, as the insurer
was already paying the high health costs related to the couple's first child's illness).
145. Racial and ethnic groups face the prospect of discriminatory genotyping by institutions as scientists uncover and identify those genetic predispositions and traits unique to
their group. RIFKIN, supra note 9, at 163. Using this genetic information, institutions can
segregate, abuse, and discriminate. Id. However, preexisting genetic conditions have
many uncertainties associated with it. Variables include: (1) the likelihood of becoming
symptomatic; (2) the time when the onset may occur; and (3) the degree of severity of a
disease, which the individual has no control over and which may be treatable. Id. at 161.
Despite these facts, a 1996 survey of genetic discrimination in the United States conducted
by the Department of Neurobiology and Division of Medical Ethics at Harvard Medical
School found the incidence of genetic discrimination growing. Id.
146. Id. at 162. J. Brian McCall is a Republican insurance executive and state legislator who authored a Texas law banning genetic discrimination by insurers. Id.
147. Diver & Cohen, supra note 93, at 1443; see also ANDREWS, supra note 67, at 18283 (discussing how some genetic testing has led to the loss of jobs or insurance, thereby
creating a movement for protection under the law against genetic discrimination).
148. Diver & Cohen, supra note 93, at 1444; ANDREWS, supra note 67, at 183 (suggesting having the genetic information remain private or stopping the tests until protective
laws are enacted).
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parties, these same restrictions prevent the use of genetic information to
withhold or grant certain privileges or benefits. 149 Insurance and employment are the primary areas where these legislative acts prohibit genetic
discrimination. The insurance legislation generally forbids asking and/or
using an applicant's genetic information to deny coverage or to assign a
higher risk classification. 5 ° The employment provisions, on the other
hand, generally restrict the use of genetic information as the basis for
various personnel actions, such as the refusal to hire, the refusal to discharge, the refusal to promote, and the assignment of unfavorable
tasks.' 5

149. See Diver & Cohen, supra note 93, at 1444. A prohibition on genetic discrimination by insurance companies, government agencies, health care providers, and schools is a
form of use restriction. Id.
150. See id. See generally ALA. CODE § 27-5-13 (2001) (prohibiting the denial of
health or disability insurance coverage because an applicant has sickle cell anemia); ALA.
CODE § 27-53-2 (2001) (prohibiting health insurers from the use or requirement of genetic
testing to determine a predisposition for cancer or to determine insurability, rates, or benefits); COLO. REV. STAT. § 1.0-3-1104.7 (2001) (providing privacy protection of genetic information and prohibiting the use of genetic information to deny access to insurance); FLA.
STAT. ANN. § 626.9707 (West 2000) (prohibiting insurers from refusing insurance or changing to higher rates for individuals with sickle cell anemia); FLA. STAT. ANN. § 760.40 (West
2000) (providing informed consent and privacy protection of genetic information); GA.
CODE ANN. §§ 33-54-1 to -8 (2000) (requiring consent prior to genetic testing, providing
privacy protection of genetic information, and prohibiting genetic testing unless for therapeutic or diagnostic purposes); Mo. ANN. STAT. § 375-1303 (West 2000) (prohibiting the
request or requirement of genetic information or genetic testing); N.H. REV. STAT. ANN.
ch. 141-H (2000) (prohibiting the consideration of genetic testing); N.C. GEN. STAT. § 5865-70 (2002) (prohibiting the refusal of health insurance because the individual has the
hemoglobin C or sickle cell trait); OR. REV. STAT. § 659A.303 (2001) (prohibiting the use
of genetic information to affect insurance coverage and providing for privacy protection
and informed consent of genetic information); WIs. STAT. ANN. § 631.89 (West 2000)
(prohibiting insurers from using genetic information as leverage against applicants); NATIONAL HUMAN GENOME RESEARCH INSTITUTE, GENETIC INFORMATION AND HEALTH IN-

SRUANCE ENACTED LEGISLATION, Insurance Chart, available at http://www.nhgri.nih.gov/

Policy-and-public.affairs/Legislation/insure.htm (last visited Dec. 18, 2002) (listing 39
states and the legislation they have enacted as of September 2000).
151. See Diver & Cohen, supra note 93, at 1444-45. See generally FLA. STAT. ANN.
§ 448.075 (West 2000) (prohibiting employers from denying employment or discharging
employees based on the sickle cell trait); IOWA CODE ANN. § 729.6 (West 1993) (prohibiting employers from requesting genetic testing or conditioning employment on a genetic
test); Mo. ANN. STAT. § 375.1306 (West 2002) (prohibiting the use of genetic information

with regard to employee benefits or rights but allowing its use when the information relates
to an employee's ability to perform assigned job tasks); N.H. REV. STAT. ANN. §§ 141-H:1
& -H:3 (1996) (prohibiting employers from using or requiring genetic testing); OR. REV.
STAT. § 659.303 (1999) (prohibiting employers from subjecting employees to genetic
screening); R.I. GEN. LAWS §§ 28-6.7-1 & 28-6.7-3 (2001) (prohibiting employers from requesting, requiring, selling, or interpreting genetic information); NATIONAL HUMAN GENOME

RESEARCH

INSTITUTE,

GENETIC
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a.

Genetic Laws in General

The scope of state legislation has evolved from early laws prohibiting
discrimination based on a few specific genetic conditions (e.g., the trait
for sickle cell anemia) to laws offering expanded protection for a wider
range of genetic afflictions."' While most states prohibit the unauthorized disclosure of genetic information, some states extend these restrictions to certain kinds of employment decisions (e.g., work assignments,
promotions, and benefits).153 As of September 2001, thirty-nine states
have some form of legislation addressing the use of genetic information.154 California, for example, has passed laws prohibiting health insurENACrTED LEGISLATION, Workplace Chart, at http://www.genome.gov/page.cfm?pagelD=
10002339 (last visited Dec. 18, 2002) (listing 24 states and the legislation they have enacted
since August 1999).
152. Diver & Cohen, supra note 93, at 1443; see also N.C. GEN. STAT. § 95-28.1 (2000)
(listing the sickle cell and hemoglobin C traits as factors employers cannot use as a basis
for employee discharge or refusal to hire); N.J. STAT. ANN. §§ 10:5-5(x) & 10:5-12(a) (West
2001) (forbidding employment discrimination based on atypical hereditary blood or cellular traits); FLA. STAT. ANN. § 448.075 (West 2000) (prohibiting employers from discharging
employees or refusing employment based on the sickle cell trait).
153. See Diver & Cohen, supra note 93, at 1444-45.

154. See ALA. CODE §§ 27-53-1 to -4 (2001); ALASKA STAT. §§ 21.54.100, 21.54.110
(Michie 2000); ARIz. REV. STAT. ANN. §§ 20-448, 20-448.02, 20-1379 (West 2002); ARK.
CODE ANN. §§ 23-86-304, 23-86-306 (Michie 2000); CAL. Civ. CODE § 56.17 (Deering
Supp. 2002); CAL. HEALTH & SAFETY CODE § 1374.7 (Deering 2002); CAL. INS. CODE
§§ 742.405-.407 (Deering Supp. 2002); CAL. INS. CODE §§ 10123.3-.35, 10123.9, 10140,
10140.1, 10143, 10146, 10148-10149.1, 10198.9, 10705 (Deering 1996 & Supp. 2002); CoLo.
REV. STAT. §§ 10-3-1104.7, 25-1-122.5 (2001); CONN. GEN. STAT. ANN. § 38a-816(19) (West

2001 & Supp. 2002);

FLA. STAT. ANN.

§ 627.4301 (West Supp. 2002);

FLA. STAT. ANN.

§§ 627.65625, 636.0201, 641.31073, 641.438, 760.40 (West 1997 & Supp. 2002); GA. CODE
ANN. §§ 33-54-1 to -8 (1996); HAW. REV. STAT. ANN. §§ 431:10A-118, 432D-26 (Michie
2001); IDAHO CODE8§ 41-2221, -3940, -4708 (Michie 1998); 215 ILL. COMP STAT. 97/20, 97/
25 (2002); IND. CODE ANN. § 16-39-5-2 (Michie 1993 & Supp. 2002); IND. CODE ANN.
§8 27-8-26, -1 to -11 (Michie 1999); IOWA CODE ANN. § 729.6 (West 1993); KAN. STAT.
ANN. § 40-2259 (2000); LA. REV. STAT. ANN. §§ 22:213.7, :250.3 (West Supp. 2002); LA.
REV. STAT. ANN. §§ 40:1299.6, :2210 (West 2001); MONT. CODE ANN. §§ 33-18-206, -22514, -22-526 (2002); NEB. REV. STAT. § 44-5246.02 (2001); NEV. REV. STAT. §§ 629.101.201, 689A.417, .545, .585, 689B.069, .420, .550, 689C.193, .198 (2001); N.H. REV. STAT.
ANN.

§§ 141-H:1 to -H:5 (1996 & Supp. 2002); N.H.

REV. STAT. ANN.

§§ 420-G:6 to -G:7

(1998 & Supp. 2002); N.J. STAT. ANN. §§ 10:5-5, :5-12 (West 1993 & Supp. 2002); N.J. STAT.
ANN. §§ 10:5-43 to -49 (West Supp. 2002); N.J. STAT. ANN. § 17:48-6.18 (West Supp. 2002);

N.J.

STAT. ANN. § 17:48A-6.11

(West Supp. 2002); N.J.

STAT. ANN. §§ 17.48E-15.2, 17B:26STAT. ANN. § 17B:30-12 (West 1996 & Supp.
2002); N.J. STAT. ANN. § 26:2J-15.1 (West Supp. 2002); N.M. STAT. ANN. §§ 24-21-1 to -7,
59A-23E-11 (Michie 2001); N.Y. EXEC. LAw 296 (McKinney 2001); N.Y. INS. LAW §§ 2612,
3221, 4305 (McKinney 2000 & Supp. 2002); N.C. GEN. STAT. §§ 58-68-30, -35, 95-28.1A

3.2, :27-36.2, :27-57 (West Supp. 2002); N.J.

(2001); N.D. CENT. CODE §§ 26.1-08-12, 36.4-03.1 (1995);
88 1751.18(D)(6), 1751.65 (West 2002); OHIo REV. CODE
3901.491, 3901.501, 3924.031, 3924.27 (Anderson 2002); OR.
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ers from refusing or canceling benefits or imposing higher rates based
upon the presence of certain genetic characteristics. 55 California laws
also bar health insurers from refusing benefits or altering terms or conditions on the basis of genetic test results unless the policy is contingent
upon testing for particular diseases and the informed consent of the appli56
cant is acquired before screening.'
The earliest state legislative efforts aimed at genetic legislation addressed discrimination in the workplace and prohibited unequal treatment based on the possession of particular genetic disorders or traits
(e.g., hemoglobin C or sickle cell carriers). 5 7 Currently, North Carolina
and Florida have laws prohibiting employment discrimination against in158
dividuals carrying the sickle cell trait.

659A.300, 192.531 - .539, 746.135 (2001); R.I. GEN. LAWS §§ 28-6.7-1 to -4 (2000); S.C.
CODE ANN. §§ 28-41-45, 38-71-670, -840, -860 (Law Co-op. 2001); S.D. CODIFIED LAWS
§§ 58-17-84, 58-18-45, 58-18B-27 (Michie 2002); TENN. CODE ANN. §§ 56-7-2701 to 7-2708,
56-7-2802 (2000); TEX. LAB. CODE § 21.401-.405 (Vernon 1996 & Supp. 2002); TEX. REV.
CIV. STAT. ANN. Art. 9032 (Vernon Supp. 2002); VA. CODE ANN. §§ 32.1-67.1 to -69.2
(Michie 1997); VA. CODE ANN. §§ 38.2-508.4, 38.2-613 (Michie 1999); W. VA. CODE ANN.
§§ 33-15-2a(g), -16-la(j), -16-3k (Michie 2000); Wis. STAT. ANN. §§ 111.372, 631.89,
632.748 (West Supp. 2001); Wvo. STAT. ANN. §§ 26-19-107, -306 (Michie 2001).
155. CAL. INS. CODE §§ 10123.3, 10140,10148,10149,11.512.95 (Deering 1996 & Supp.

2002);

CAL. HEALTH & SAFETY CODE

§§ 1374.7, 11512.95 (Deering 2002).

156. CAL. INS. CODE §§ 10148, 10123.3, 10140 (Deering 1996 & Supp. 2002); FLA.
STAT. ANN. ch. 448.076 (West 2002); Miller, supra note 142, at 259.
157. Miller, supra note 142, at 259.
158. N.C. GEN. STAT. § 95-28.1 (2002) (prohibiting employment discrimination
against individuals with the hemoglobin C or sickle cell traits); FLA. STAT. ANN. ch. 448.076
(West 2002) (preventing employers from requiring prospective employees to undergo
screening for the sickle cell trait); see Miller, supra note 142, at 259. Other states with
legislation like Florida and North Carolina include Alabama, New Jersey, and New York.
ALA. CODE § 27-5-13 (1986); N.J. STAT. ANN. §§ 10:5-5, 10:5-12 (West 1993 & Supp. 2002);
N.Y. Civ. RIGHTS LAW § 48-a (McKinney 1992 & Supp. 2002). Louisiana's statute prevents genetic discrimination in the workplace against individuals with the sickle-cell trait.
LA. REV. STAT. ANN. § 23:352 (West 1998); see Miller, supra note 142, at 260. New Jersey's
statute proscribes against discrimination for individuals carrying the sickle cell, hemoglobin, thalassemia, Tay-Sachs, and cystic fibrosis traits. N.J. STAT. ANN. § 10:5-12-12 (West
1993); see Miller, supra note 142, at 260. Finally, New York's statute protects individuals
with sickle cell, Tay-Sachs, and the beta-thalassemia traits from discrimination. N.Y. Civ.
RIGHTS LAW § 48-a (McKinney 1992); see Miller, supra note 142, at 260.
New York and New Jersey's general statutes include prohibitions on genetic discrimination in employment practices (i.e., hiring, discharging, and fixing terms and conditions of
employment). N.J. STAT. ANN. § 10:5-12 (West 1993 & Supp. 2002); N.Y. EXEC. LAW § 296
(McKinney 2001); see Miller, supra note 142, at 263. Although New York limits its coverage to asymptomatic genetic characteristics, New Jersey's statute does not. Compare N.J.
STAT. ANN. § 10:5-12 (West 1993 & Supp. 2002), with N.Y. EXEC. LAW § 296 (McKinney
2001) (stating discrimination on the basis of "genetic predisposition or carrier status" is
prohibited). See Miller, supra note 142, at 263.
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Some states, like Arizona, Iowa, and New Hampshire, have passed

more comprehensive statutes forbidding employers from discriminating

against individuals based on the result of genetic tests.' 59 Several states
provide additional employment protection by barring discrimination on
the basis of genetic information obtained not from genetic tests but from
other sources. 16 1 Other states, however, prohibit employers from administering, requiring,
or soliciting genetic tests as a condition to
1
16

employment.

A few states, such as Iowa, New Hampshire, and Wisconsin, forbid employers from requiring their employees to take genetic tests.162 Iowa,
Rhode Island, and Wisconsin broaden this prohibition by prohibiting dis163
crimination against persons who have voluntarily taken genetic tests.

Finally, there are states that provide an exception to the confidentiality of
genetic information with the employee's consent. 164
b.

Problems With State Laws

Despite the intentions of these state laws, flaws exist: the uninsured,
unemployed, and self-insured employers are not generally regulated
under these laws.' 6 5 Most of these laws focus on the genetic test, not on
the information generated by other sources capable of providing similar
information (e.g., medical records or family history). 166 These laws provide inconsistent protection because they vary from
broad protection to
67

narrow protection against genetic discrimination.'

159. ARIz. REV. STAT. ANN. § 41-1463(B) (West 2001); N.H. REV. STAT. ANN. § 141H:31(a) (2001); N.Y. Civ. Riorrs LAW § 48-a (McKinney 1992); Wis. STAT. ANN.
§ 111.372(1)(a) (West 2000); Miller, supra note 142, at 260.
160. Miller, supra note 142, at 261; e.g., N.C. GEN. STAT. § 95-28.1A (2001) (including
information from genetic testing or counseling services or from "information obtained concerning the person or a member of the person's family").
161. IOWA CODE ANN. § 729.6.2 (West 1993); N.H. REV. STAT. ANN. § 141-H:31(a)
(1996); N.Y. Civ. RIGHTS LAW § 48-a (McKinney 1992); OR. REV. STAT. § 659A.303(1)
(2001); R.I. GEN. LAWS § 28-6.7-1(a)(1) (2000); TEX. LAB. CODE ANN. § 21.402(a)(2)
(Vernon 2001 & Supp. 2002); Wis. STAT. ANN. §111.372(1)(a) (West 1999); see Miller,
supra note 142, at 261.

162. IOWA CODE ANN. § 729.6(2) (West 1993); N.H. REV. STAT. ANN. § 141-H:31(a)
(1996); Wis. STAT. ANN. § 111.372(1)(a) (West 1990); see Miller, supra note 142, at 261.
163. IOWA CODE ANN. § 729.6(2)(b) (West 1993); R.I. GEN. LAWS § 28-6.7-1(a)(2)
(2000); Wis. STAT. ANN. § 111.372(1)(b) (West 2002); Miller, supra note 142, at 261.
164. IOWA CODE ANN. § 729.6(7) (West 1993); N.H. REV. STAT. ANN. § 141-H:3(IV)
(1996); N.Y. EXEC. LAW § 296(19)(d) (McKinney 2001); Wis. SrAT. ANN. § 942.07(3)
(West 1996); Miller, supra note 142, at 261.
165. See Jeremy A. Colby, Note, An Analysis of Genetic Discrimination Legislation
Proposed by the 105th Congress, 24 AM. J.L. & MED. 443, 465-67 (1998).
166. Id. at 466.
167. Id.
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Colorado, for example, has four premises by which it regulates the use
of genetic information:
(a) Genetic information is the unique property of the individual to
whom the information pertains;
(b) [Genetic testing information] may be subject to abuse if disclosed to unauthorized third parties without the willing consent
of the individual to whom the information pertains;
(c) To protect individual privacy and to preserve individual autonomy with regard to the individual's genetic information, it is appropriate to limit the use and availability of genetic information;
(d) The intent of this statute is to prevent information derived from
the genetic testing from being used to deny access to health are
insurance, group disability insurance, or long-term care insurance coverage.' 6 8
This coverage regulates the use of genetic testing. The Colorado statute characterizes information obtained through genetic testing as privileged and confidential except when used in treatment, diagnosis, or
therapy or, when used for other purposes, with the written consent of the
person tested.1 69 Unfortunately, the statute applies only to entities providing long-term care, group disability, or health insurance but not to self70
insured individuals.1
In addition, few state laws specifically address the restriction of the dissemination of genetic information in the insurance arena despite requiring the equitable and fair treatment of parties.17 ' Before 1986, existing
state laws prohibiting genetic discrimination had a narrow scope. 172 Yet,
since 1990 with the start of the Human Genome Project, states have expanded their laws to include protections against most genetic
173
conditions.

168. COLO. REV. SI-AT. § 10-3-1104.7(1)(a)-(d) (2001); cf Coleman, supra note 75, at
161-64 (addressing a state's reasons for preventing gene manipulation in the context of
genetically molding or creating a child).
169. COLO. REV. STAT. § 10-3-1104.7(3)(a) (2001).
170. CoLo. REV. STAT. § 10-3-1104.7(3)(b) (2001).
171. French, supra note 142, at 170-71.
172. See id. at 171.
173. CAL. CIv. CODE § 56.17 (Deering Supp. 2002); CAL. INS. CODE §§ 10123.3,
10123.31, 10123.35, 10140, 10140.1, 10143, 10146, 10148, 10149, 10149.1 (Deering 1996 &
Supp. 2002); CAL. HEALTH & SAFETY CODE §§ 1374.7, 1374.9 (Deering 2002); COLO. REV.
STAT. § 1.0-3-1104.7 (2001); FLA. STAT. ANN. § 760.40 (West 1997 & Supp. 2002); GA.
CODE ANN. §§ 33-54-1 to -8 (1996); MINN. STAT. ANN. § 72A.139 (West 1999); N.H. REV.
STrAT. ANN. §§ 141-H:I to :6 (1996 & Supp. 2002); OHIO REV. CODE ANN. § 3901.49 (in
effect until Feb. 9, 2004 then to be replaced by § 3901.491), 3901.50 (Anderson 2001); OR.
REV. STAT. §§ 192.533, 192.535, 192.537, 192.539, 746.135 (2001); Wis. SIAT. ANN. § 631.89
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California has one of the strongest genetic testing laws in the United
States due to its extensive coverage of genetic characteristics, such as Tay174
Sachs trait, Thalassemia trait, sickle cell trait, and X-linked hemophilia.
Furthermore, California law prohibits insurance companies from fixing
fees or rates based on genetics. 1 75 Finally, California law requires a writobtained from an applicant before insurers can
ten informed consent be
76
request a genetic test.1
In 1992, Wisconsin became the first state "to ban the use of genetic
testing" in health insurance underwriting.' 77 The Wisconsin statute prohibits the insurer from denying coverage or continued coverage and from
increasing insurance premiums on the basis of whether or not a genetic
test has been taken or on the results of such tests. 178 Furthermore, the
statute forbids requiring or requesting family members "to obtain a geto reveal such a test was taken, or to give the results of such
netic test,"
79
tests.'
Arizona and Montana laws prevent insurance companies from refusing
to consider applicants or from fixing rates, terms, or conditions on the
basis of genetic discrimination. "0 Such action "constitutes unfair discrimination unless the applicant's medical condition and history and either claims experience or actuarial projections establish that substantial
differences in claims are likely to result from the genetic condition."''
Thus, if insurers provide justification, they can use genetic information in
assessing risk.

(West 1995 & Supp. 2001); see also French, supra note 142, at 171 (noting ten states have
passed laws protecting against genetic discrimination since 1990).
174. CAL. INS. CODE § 10143 (Deering 1996); see also French, supra note 142, at 172
(complimenting California's strong genetic testing).
175. CAL. INS. CODE § 10143 (Deering 1996); see French, supra note 142, at 171-72
(discussing the regulation of insurance fees and rates in relation to genetics).
176. CAL. INS. CODE § 10148(a) (Deering Supp. 2002).
177. WIs. STAT. ANN. § 631.89 (West 1995 & Supp. 2001); see French, supra note 142,

at 171.
178. Wis. STAT. ANN. § 631.89 (2)(a)-(d) (West 1995 & Supp. 2001); see French, supra
note 142, at 171.
179. WIs. STAT. ANN. § 631.89 (2)(a)-(b) (West 1995 & Supp. 2001); see French, supra
note 142, at 171.
180. ARIz. REV. STAT. ANN. § 20-448(D) (West 2002); MONT. CODE ANN. § 33-18206(3) (2002).
181. MONT. CODE ANN. § 33-18-206(4) (2002); see ARIZ. REV. STAT. ANN. §§ 20448(E) & (F) (West 2002).
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Florida also requires informed consent."' s Florida law provides for the
person tested to have the exclusive property rights over the results. 183
These results are confidential and cannot be disclosed without the per85
son's consent.1 84 A violation of this requirement is a misdemeanor.'
An entity performing a test must notify the person tested that the infor186
mation was received and specify how it was used.
The Iowa genetic testing statue defines "genetic testing" as:
a test of a person's genes, gene products, or chromosomes, for abnormalities or deficiencies, including carrier status, that are linked to
physical or mental disorders or impairments, or that indicate a susceptibility to illness, disease, impairment, or other disorders, whether
physical or mental, or that demonstrate genetic or chromosomal
damage due to environmental factors. 8 7
However, this law pertains only to employment-related discrimination.' 88 It prohibits employers from requiring a genetic test from current
or potential employees and from using genetic information as a term or
condition of employment.' 8 9
New Hampshire also has a sweeping genetic law that prohibits genetic
testing as a requirement to conduct business between individuals and
their family members.' 90 The New Hampshire statute defines "genetic
testing" as:
a test, examination, or analysis which is generally accepted in the
scientific and medical communities for the purpose of identifying the
presence, absence, or alteration of any gene or chromosome, and any
report, interpretation, or evaluation of such a test, examination, or
analysis, but excludes any otherwise lawful test, examination, or
analysis that is undertaken for the purpose of determining whether
an individual meets reasonable functional standards for a specific job
or task.19

182. FLA. STAT. ANN. § 760.40 (West 1997 & Supp. 2002).
183. FLA. STAT. ANN. § 760.40(2)(a) (West 1997 & Supp. 2002); see also French, supra

note 142, at 173 (stating Florida provides that genetic tests are the exclusive property of the
person tested).
184. FLA. STAT. ANN. § 760.40(2)(a) (West 1997 & Supp. 2002).
185. FLA. STAT. ANN. § 760.40(2)(b) (West 1997 & Supp. 2002); see also French, supra
note 142, at 173.
186. FLA. STAT. ANN. § 760.40(3) (West 1997 & Supp. 2002); see also French, supra
note 142, at 173.
187. IOWA CODE ANN § 729.6(1)(c) (West 1993).
188. Id.
189. Id.; see also French, supra note 142, at 173.
190. N.H. REV. STAT. ANN. ch.141-H (1996 & Supp. 2002).
191. N.H. REV. STAT. ANN. § 141-H:1(IV) (1996).
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Under the New Hampshire law, health insurers may not ask whether
an individual has taken a genetic test, require a genetic test, set rates or
benefits on the basis
of a genetic test, or condition coverage on the results
19 2
testing.'
of genetic
Hailed as the strictest genetic privacy act in the United States,' 93 Oregon's law is based on legislative findings that "[t]he improper collection,
retention or disclosure of genetic information can lead to significant harm
to an individual. . .including stigmatization and discrimination in areas
such as employment, education, health care and insurance. '194 Oregon
law prohibits a possessor of genetic information from disclosing it, allowing very few exceptions (e.g., specific court order, authorized by state,
written consent).19 5 The statute also requires anyone who seeks to obtain
genetic information
from an individual first acquire that individual's in96
formed consent.'

These state laws reflect a collective trend toward greater protection in
the areas of insurance and employment laws. The breadth of these laws
covers the regulation
of genetic testing and the protection of genetic
197
information.
2. Federal Laws
Currently no federal statute exists that explicitly addresses genetic discrimination; however, protection against such actions could possibly be
inferred from a number of federal laws,1 98 such as the American with
Disabilities Act (ADA) of 1998,"9 President Clinton's Executive Order 210 prohibiting genetic discrimination in federal employment, and the
Health Insurance Portability and Accountability Act (HIPAA) of 1996.201

192. See N.H. REV. STAT. ANN. § 141-H:4 (1996).
193. See French, supra note 142, at 173.
194. OR. REV. STAT. § 192.533(1)(c) (2001).
195. See generally OR. REV. STAT. §§ 192.537, -.539 (2001) (listing the exceptions to
the disclosure of genetic information).
196. 2001 Or. Laws Ch. 388 (OR. REV. STAT. § 659.710 (1999)).
197. See French, supra note 142, at 174.
198. See Miller, supra note 142, at 237.
199. See Americans with Disabilities Act of 1990, 42 U.S.C. §§ 12111-12117 (2001)
(prohibiting genetic discrimination in the workplace).
200. Exec. Order No. 13,145, 3 C.F.R. 235 (2001), available at 42 U.S.C. § 2000e-16.
201. See Health Insurance Portability and Accountability Act of 1996, 29 U.S.C.
§§ 1181-1183 (2001) (restricting genetic discrimination in the insurance arena).
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Americans With Disabilities Act of 1990

The ADA prohibits genetic discrimination in the workplace.2 °2 Although this protection against genetic discrimination is not explicitly
stated, Subchapter I of the ADA protects individuals from discrimination
on the basis of disability. 2°3 The Act's broad language covers hiring, discharge, promotion, and other conditions and terms of employment from
which discrimination is prohibited.20 4 The ADA defines "disability" as a
condition in which physical or mental impairments
limits substantially a
20 5
person's performance in a major life activity.
In 1995, the Equal Employment Opportunity Commission (EEOC) issued a guideline interpreting the ADA's application to pre-symptomatic
individuals having a genetic predisposition for a disabling condition. 0 6
The policy guideline states employers violate the ADA when they discriminate against individuals "on the basis of a genetic predisposition to
an illness, disease, or other disorder" whether or not the condition has
manifested.20 7
Thus, the ADA covers individuals having a history of genetically related disabilities and those individuals who have a predisposition for genetically related illnesses or disabilities that manifests themselves and
greatly impairs a major life activity.20 8 The ADA also provides other protections: it prohibits the discrimination against individuals who associate
with people with disabilities, prohibits hiring practices that injure workers
based on their genetic makeup, and protects individuals from discrimination in the workplace who express asymptomatic genetic conditions.20 9
Nevertheless, these interpretations are not binding.21 0 They have yet
to be tested in the courts.211 The ADA's definition of "disability" focuses
on the nature not on the cause of an individual's functional limitation.2 12
202. See 42 U.S.C. §§ 12111-12117 (2001).
203. See Diver & Cohen, supra note 93, at 1450; Miller, supra note 142, at 238.
204. See Miller, supra note 142, at 238.
205. 42 U.S.C. §§ 12111-12117 (2000); Miller, supra note 142, at 238.
206. 2 EEOC COMPL. MAN (BNA) § 902:0045 (1995); Miller, supra note 142, at 239.
207. Miller, supra note 142, at 239.
208. Id. at 238-39.
209. Id. at 239-41.
210. See Diver & Cohen, supra note 93, at 1450; Miller, supra note 142, at 241.
211. The ADA provides some workplace protections against genetic discrimination
but the scope of these protections have yet to be protected in the courts. See James M.
Jeffords & Tom Daschle, PoliticalIssues in the Genome Era, 291 SCI. 1249, 1250 (2001).
212. See 42 U.S.C. § 1.2102(2) (2000).
(2) DISABILITY.-The term "disability" means, with respect to an individual(A) a physical or mental impairment that substantially limits one or more of the
major life activities of such individual;
(B) a record of such an impairment; or
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Plus, the employer may use and obtain information of the employee's
medical history and condition at the placement stage of hiring.2 13 For
example, in Olson v. General Electric Astrospace,21 4 Olson alleged his
former employer, General Electric, did not hire him because he suffered
from depression, multiple personality disorder, and post traumatic stress
disorder. 21 5 Although the employer did not know of Olson's condition,
General Electric was aware he suffered from some illness as reported
through his performance evaluations.21 6 Nonetheless, the Third Circuit
Court of Appeals found Olson did not show he was disabled or had a
record of impairment.2 1 7
Additionally, coverage under the ADA requires a physical impairment
that substantially limits a major life activity.2 18 Another problem with the
ADA is that it requires employers to make only "reasonable accommodations" for the disabled person to perform the jobs he or she would otherwise not be equipped to perform. 1 9

(C) being regarded as having such an impairment.

Id.; see Diver & Cohen, supra note 93, at 1452.
213. See id. at 1450-51.
214. Olson v. General Electric Astrospace, 101 F.3d 947 (3d Cir. 1996).
215. Olson, 101 F.3d at 950.
216. Olson, 101 F.3d at 954-55. But see generally Geraci v. Moody Tottrup Int'l, Inc.,
82 F.3d 578 (3d Cir. 1996) (stating the plaintiff offered no evidence that her manager knew
she was pregnant in her pregnancy discrimination suit).
217. Olson, 101 F.3d at, 952.
218. 42 U.S.C. § 12102 (2) (2001) (stating "[tihe term 'disability' means, with respect
to an individual-(A) a physical or mental impairment that substantially limits one or
more of the major life activities of such individual"); see Miller, supra note 142, at 243
(explaining the ADA's definition of "disability").
219. 42 U.S.C. § 12112 (2001). The ADA's requirements include the following:
(a) GENERAL RULE.-No covered entity shall discriminate against a qualified individual with a disability because of the disability of such individual in regard to job
application procedures, the hiring, advancement, or discharge of employees, employee
compensation, job training, and other terms, conditions, and privileges of
employment.
(b) CONSTRUCTION.-As used in subsection (a), the term "discriminate" includes(5)(A) not making reasonable accommodations to the known physical or mental
limitations of an otherwise qualified individual with a disability who is an applicant or employee, unless such covered entity can demonstrate that the accommodation would impose an undue hardship on the operation of the business of such
covered entity; or
(B) denying employment opportunities to a job applicant or employee who is an
otherwise qualified individual with a disability, if such denial is based on the need
of such covered entity to make reasonable accommodation to the physical or
mental impairments of the employee or applicant.
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However, not all carriers for certain genetic traits or disorders result in
a physical impairment that substantially limits a major life activity. For
example, in Murphy v. United Parcel Service Inc.,220 the Court ruled hypertension was not a disability under the ADA.22 1 On the other hand,
the Second Circuit Court of Appeals in Heyman v. Queens Village Committee for Mental Health for Jamaica Community Adolescent Program,
Inc.,22 concluded Heyman's employer discriminated against him when he
was fired for the physical impairment he developed from his
lymphoma. 2 3
Furthermore, the ADA authorizes the states to regulate matters relating to insurance and genetic issues.2 2 4 No specific provision mentions genetic discrimination, thereby raising the question of whether "disability"
under the ADA covers genetic conditions. 2 5 The ADA considers only
mental or physical impairments that substantially limit a major life activity as disabilities.22 6 Thus, if an individual carries a gene for a disease yet
Id.; see Diver & Cohen, supra note 93, at 1450; see also 42 U.S.C. § 12111 (8) & (9) (2001).
The ADA defined "qualified individual with disability" and "reasonable accommodations"
as the following:
(8) QUALIFIED INDIVIDUAL WITH A DISABILITY.-The term "qualified individual with a disability" means an individual with a disability who, with or without
reasonable accommodation, can perform the essential functions of the employment
position that such individual holds or desires. For the purposes of this title, consideration shall be given to the employer's judgment as to what functions of a job are essential, and if an employer has prepared a written description before advertising or
interviewing applicants for the job, this description shall be considered evidence of the
essential functions of the job.
(9) REASONABLE ACCOMMODATION.-The term "reasonable accommodation" may includemaking existing facilities used by employees readily accessible to and usable by individuals with disabilities; and
(B) job restructuring, part-time or modified work schedules, reassignment to a vacant
position, acquisition or modification of equipment or devices, appropriate adjustment
or modifications of examinations, training materials or policies, the provision of qualified readers or interpreters, and other similar accommodations for individuals with
disabilities.
Id.
220. Murphy v. United Parcel Serv. Inc., 527 U.S. 516 (1999).
221. Murphy, 527 U.S. at 524.
222. Heyman v. Queens Vill. Comm. For Mental Health for Jamaica Cmty. Adolescent Program, Inc., 198 F.3d 68 (2d Cir. 1999).
223. Heyman, 198 F.3d at 73.
224. 42 U.S.C. §§ 12111-12117 (1994).
225. Miller, supra note 142, at 238.
226. 29 C.F.R. § 1630.2(g) (2001); Miller, supra note 142, at 238-39; Rachinsky, supra
note 37, 591 (quoting the EEOC guidelines regarding the definition of disability). The
ADA defines "disability" as "a physical or mental impairment which substantially limits
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to be expressed, coverage under ADA becomes problematic.22 7 Prohibition of discrimination against these individuals may not be covered, because the ADA does not directly address this issue.2 28 Congress basically
constructed the ADA for people with phenotypic disabilities, 229 but with
the advent of the Human Genome Project and with the increased understanding of diseases and conditions, a change in either the ADA's definition of "disability" or people's perception of what constitutes a disability
must occur.2 3 °
b.

Title VII of the Civil Rights Act

Another federal law that may provide protection against forms of genetic discrimination is Title VII of the Civil Rights Act of 1964,23 a which
relates to national origin, race, religion, and gender.2 32 Genetic screening
is considered to be a facially neutral policy, thus, claims succeeding under
the protection of this Act must demonstrate a disparate impact theory.2 33
With most genetically related diseases and disorders having yet to disproportionately affect one of Title VII's protected classes, this Act may not
provide ample protections against genetic discrimination in the
workplace.23 4
c.

Health Insurance Portability and Accounting Act of 1996

The Health Insurance Portability and Accounting Act [HIPAA] of
1996,235 the first federal law addressing genetic discrimination,2 3 6 deals
primarily with genetic discrimination in insurance through the restriction
of the extent to which health insurance plans can exclude coverage to

one or more of that person's major life activities." 29 C.F.R. § 1630.2(h) (2001). This term
does not include "characteristic predisposition to illness or disease." Id.
227. See Miller, supra note 142, at 238 (stating the ADA does not explicitly mention

genetic discrimination).
228. Rachinsky, supra note 37, 591-92 (stating there is virtually no case law on point

to determine how much protection the ADA provides against genetic discrimination);
Colby, supra note 165, at 467 (stating without judicial delineation, the ADA offers only
limited protection against genetic discrimination). But see Miller, supra note 142, at 238
(noting several cases in which the ADA covers individuals with genetically related
disabilities).

229. Phenotypic disabilities are those that are expressed.

230. See Rachinsky, supra note 37, 584 (declaring a need to amend the definition of

"discrimination" under the act).
231. 42 U.S.C. §§ 2000e - 2000e -16(e) (2001).
232. Miller, supra note 142, at 247.
233. Id. at 248.
234. Id.
235. 29 U.S.C. § 1182(a)(1) (1999).
236. French, supra note 142, at 168.
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individuals with a genetic predisposition.2 3 7 Without diagnosis, genetic
information or susceptibility to genetic disorders cannot constitute a preexisting condition and cannot be used to limit access to health insurance. 238 Unfortunately, gaps in the protections exist. HIPAA applies
only to group health insurance plans. 2 39 Those individuals who buy insur-

237. Diver & Cohen, supra note 93, at 1449; Jeffords & Daschle, supra note 211, at
1250.
238. 29 U.S.C. § 1182(a)(1) (1999). HIPAA's rules on preexisting conditions are as
follows:
(a) Limitation on preexisting condition exclusion period; crediting for periods of previous coverage
Subject to subsection (d) of this section, a group health plan, and a health insurance
issuer offering group health insurance coverage, may, with respect to a participant or
beneficiary, impose a preexisting condition exclusion only if(1) such exclusion relates to a condition (whether physical or mental), regardless
of the cause of the condition, for which medical advice, diagnosis, care, or treatment was recommended or received within the 6-month period ending on the enrollment date;
(2) such exclusion extends for a period of not more than 12 months (or 18 months
in the case of a late enrollee) after the enrollment date; and
(3) the period of any such preexisting condition exclusion is reduced by the aggregate of the periods of creditable coverage (if any, as defined in subsection (c)(1) of
this section) applicable to the participant or beneficiary as of the enrollment date.
(b) Definitions
For purposes of this part(1) Preexisting condition exclusion
The term "preexisting condition exclusion" means, with respect to coverage, a
limitation or exclusion of benefits relating to a condition based on the fact that the
condition was present before the date of enrollment for such coverage, whether or
not any medical advice, diagnosis, care, or treatment was recommended or received before such date.
(B) Treatment of genetic information
Genetic information shall not be treated as a condition described in subsection (a)(1) of this section in the absence of a diagnosis of the condition related
to such information.
Id.; see Miller, supra note 142, at 255.
239. Health Insurance Portability and Accounting Act of 1996, Pub. L. No. 104-191,
110 Stat. 1936 (stating in Title XXVII subpart 2 that the provisions are applicable only to
health insurance issuers); 42 U.S.C. § 300gg-l1 (2000). HIPAA's provisions on group
health insurance includes the following:
(a) Issuance of coverage in the small group market
(1) In general
Subject to subsections (c) through (f) of this section, each health insurance
issuer that offers health insurance coverage in the small group market in a
State(A) must accept every small employer (as defined in section 300gg-91(e)(4)
of this title) in the State that applies for such coverage; and
(B) must accept for enrollment under such coverage every eligible individual
(as defined in paragraph (2)) who applies for enrollment during the period in

https://commons.stmarytx.edu/thescholar/vol5/iss1/6

36

Chico: Pharmacogenomics: A Brave New World in Designer Drugs.

2002]

PHA RMACOGENOMICS

ance outside of employment-based plans (i.e., the individual market) and
the unemployed are not covered under HIPAA. 240 Additionally, HIPAA
does not24prohibit
the requirement of or the request for genetic tests by
1
insurers.

Other failures in HIPAA include its inability to address genetic privacy
concerns (e.g., the dissemination of genetic information).2 4 2 Secondly, it
fails to regulate or prohibit insurers' genetic testing requirements. 243 Finally, it fails to prohibit employer discrimination against people seeking
health insurance.2 4 4
d.

President Clinton's Executive Order

Former President Clinton issued Executive Order 13,145 on February
8, 2000, To Prohibit Discrimination in Federal Employment based on Genetic Information (the Genetic Executive Order).24 5 Under the Genetic
Executive Order, federal agencies and departments cannot discriminate
against an applicant for employment, an employee, or former employee
with respect to hiring practices (e.g., promotion, discharging, and hiring)
and terms of employment (e.g., compensations, conditions, privileges) on
the basis of genetic information. 4 6 The Order also prohibits classification of employees based on protected genetic information.24 7 It forbids

which the individual first becomes eligible to enroll under the terms of the
group health plan and may not place any restriction which is inconsistent with
section 300gg-1 of this title on an eligible individual being a participant or
beneficiary.
(b) Assuring access in the large group market.
Id.; see Jeffords & Daschle, supra note 211, at 1250.
240. See Diver & Cohen, supra note 93, at 1449-50; Jeffords & Daschle, supra note
211, at 1250; Miller, supra note 142, at 255.
241. See Jeffords & Daschle, supra note 211, at 1250; Miller, supra note 142, at 256.
242. Miller, supra note 142, at 255-56. See generally Diver & Cohen, supra note 93
(discussing genetic privacy in the insurance arena); Jeffords & Daschle, supra note 211
(stating "the greatest difficulty will be for policy-makers to strike a balance between timely
promotion and use of the best genetic research and careful protection of people from genetic discrimination")
243. Miller, supra note 142, at 255-56.
244. Id.
245. See Exec. Order No. 13,145, 3 C.F.R. 235 (2001), available at 42 U.S.C. § 2000e16; Diver & Cohen, supra note 93, at 1451; Miller, supra note 142, at 248.
246. See Jeffords & Daschle, supra note 211, at 1250; Miller, supra note 142, at 249.
247. See generally Exec. Order No. 13,145, 3 C.F.R. 235 (2001) (requiring "[t]he employing department or agency.. .not disclose protected genetic information with respect to
an employee, or information about a request for or the receipt of genetic services by an
employee" and "[tlhe employing department or agency shall not request, require, collect,
or purchase protected genetic information with respect to an employee, or information
about a request for or the receipt of genetic services by such employee").
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the disclosure of genetic information and the requirement or request for
genetic testing as a condition of being hired.24 8
Under the Genetic Executive Order, genetic discrimination against
federal employees by federal departments and agencies is prohibited except during the pre-placement stage where genetic information can be
used.2 49 Title VII provides for the disclosure of genetic information
under limited circumstances: to the individual, the subject of the genetic
tests, to a health researcher under certain circumstances, to a court of
competent jurisdiction under the order of a subpoena, and to investigating officials of the executive branch acting in compliance with the Genetic
Executive Order where the genetic information is relevant to the
investigation.250
e.

Problems With Federal Legislation

Despite the federal legislation, none of it defines the genetic conditions
to be protected. Do the genetic conditions include only the well-established, clinically defined diseases? Or, does it also consist of the syndromes and functional incapacities of individuals? Does addictiveness,
compulsiveness, or other patterns of behavior factor in the determination
of what constitutes "genetic" in genetic discrimination?2 5 1 Finally, these
legislations permit adverse treatment of symptomatic individuals but prohibits such treatment against asymptomatic individuals.2 52
As scientific information grows exponentially to outpace the surging
social and legal issues, a special genetic legal regime is required. In general, the few existing state restrictions are weak because of the rapid pace
of science and the dynamic nature of genetics. 3 Despite stronger federal legislation, a special genetic legal regime is still required. Current
legislation is insufficient to provide the afforded protections - they do not
explicitly address the regulation and prohibition of genetic information
and genetic testing.254 Although current laws such as HIPAA are steps in
the right direction, more is needed in the form of either discrete statutes
for discrete problems or a comprehensive uniform act.

248. See Miller, supra note 142, at 250.
249. Diver & Cohen, supra note 93, at 1451. See Miller, supra note 142, at 250.
250. See Exec. Order No. 13,145, 3 C.F.R. 235 (2001), available at 42 U.S.C. § 2000e16; Miller, supra note 142, at 250.
251. See Diver & Cohen, supra note 93, at 1451.

252. See id. at 1452.
253. See French, supra note 142, at 175.

254. See id.
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B. Applicability to Pharmacogenomics
What makes pharmacogenomics different from other genetic fields is
that it uses genetic information to create drugs for specific individuals.
Pharmacogenomics attempts to predict when patients experience toxicity
or side effects and to reduce adverse drug reactions. Molecular genotyping identifies these poor metabolizers who are predisposed to such suffering. 5 Thus, misuse of genetic information can result. For example, the
information can be sold to pharmaceutical companies to pinpoint individuals genetically fit for their drugs. Additionally, the knowledge that diseases and disorders are linked to population groups identified by ethnic
categories, economic status, and gender must guide policy makers away
from America's eugenic past of sterilization laws.
1.

Constitutional Analysis

The Fourteenth Amendment 256 provides no person shall be denied
equal protection of the law by any state.2 5 7 Federal classifications (i.e.,
fundamental rights or suspect classifications) that do not promote a compelling governmental interest violate the Due Process Clause.2 5 8 The
Equal Protection Clause guarantees similar individuals be dealt with in a
similar manner by the government.2 5 9
United States v. Carolene Products Co. 260 provides the criteria for
which strict scrutiny may be applied:
Nor need we enquire whether similar considerations enter into the
review of statutes directed at particular religious, or national, or racial minorities, whether prejudice against discrete and insular minori-

255. See Bullock, supra note 129, at 53-54.

256. See U.S.

CONST.

amend. XIV.

257. See U.S. CONST. amend. XIV § 1. The Fourteenth Amendment applies to states.
Id. There is no equal protection clause governing the federal government, but the federal
government infers a Fifth Amendment equal protection guarantee through the Due Process Clause. See U.S. CONST. amend V.
258. See generally Adarand Constructors, Inc. v. Pena, 515 U.S. 200 (1995) (applying
the strict scrutiny test to examine even benign uses of race classification); Boiling v.
Sharpe, 347 U.S. 497 (1954) (establishing the congruence of the Equal Protection guarantee of the Fifth Amendment).
259. Cf Reed v. Reed, 404 U.S. 71 (1971) (stating sex cannot be the basis for determining whether an individual may be an estate executor). Three standards of review exist
in an equal protection analysis: the Rational Relation test (the means the government
takes must rationally related to a governmental end to survive), Strict Scrutiny test (provides no deference to the government because the government has to show a compelling
interest), and the Intermediate Test (requires the governmental means to have a "substantial relationship" to an "important" governmental interest). See JOHN E. NOWAK & RONALD D. ROTUNDA, EDS., CONSTITUTIONAL LAW 639-641(6th ed. 2000).
260. United States v. Carolene Products Co., 304 U.S. 144 (1938).
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ties may be a special condition, which tends seriously to curtail the
operation of those political processes ordinarily to be relied upon to
protect minorities, and which may call for a correspondingly more
searching judicial inquiry.2 6 '
Can individuals with abnormal genetic traits be considered a suspect
class, and therefore guarded under the Equal Protection Clause? The
criteria to identify a suspect class include the application of strict scrutiny,
as the classification focuses on "immutable characteristics over which individuals identified by such characteristic have no control., 262 Suspect
classifications include classifying individuals as members of a racial minority or on the basis of ancestry (national origin).26 3 Suspectness is also
found in a group's status of being a "discrete and insular minority" and
having a group's defining quality of being "immutable. '264 Courts genermemberally focus on the "'stigma' and 'opprobrium"' attached to the
2 65
treatment.
unequal
in
results
that
group
ship in a particular
In Frontiero v. Richardson,266 the immutable characteristic was sex,
which the Court found to be like race and national origin - all "determined solely by the accident of birth., 26 7 The Court further held:
[W]hat differentiates sex from such nonsuspect statuses as intelligence or physical disability, and aligns it with the recognized suspect
criteria, is that the sex characteristic frequently bears no relation to
ability to perform or contribute to society. As a result, statutory distinctions between the sexes often have the effect of invidiously relegating the entire class of females to inferior legal status without
regard to the actual capabilities of its individual members.2 68
A similar comparison can be made with genetic predispositions, because the genetic variations among individuals have no relation to their
function as members of society.26 9 Statutory distinctions on genetic information can have the comparable invidious effect of relegating individuals
to an inferior legal status.2 7 0

261. Carolene Products Co., 304 U.S. at 152-53 n.4.
262. Smith & Burns, supra note 15, at 43-44.
263. Nowak & Rotunda, supra note 259, at § 14.3.
264. Id. at § 14.3.
265. See Smith & Burns, supra note 15, at 44 n.116.
266. Frontiero v. Richardson, 411 U.S. 677 (1973) (introducing the concept of possessing an immutable characteristic as a basis for identifying suspect classifications).
267. Frontiero, 411 U.S. at 686 (introducing the concept of possessing an immutable
characteristic as a basis for identifying suspect classification).
268. Frontiero, 411 U.S. at 686-87.
269. Smith & Burns, supra note 15, at 45.
270. Id.
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Until technology exists to change an individual's genetic makeup, individuals possessing genetic defects that do not inhibit their functionality
should fall under the protection of suspect classification.27 1 The extent to
which genetic markers affect one's functionality differs. Although
asymptomatic individuals carry a defective gene, they have a higher likelihood of developing the disease. 7 2 Heterozygous individuals merely
carry the genetic information of a disease, which will be passed on to
their progeny, and remain asymptomatic. 273 Take, for example,
haemophilia: females may carry the gene for haemophilia without experiencing the effect of intense bleeding with even the lightest of bruises,
whereas male members of the family exhibit the phenotypical manifestations of the disease. Then, there are those individuals who possess one or
more genetic polymorphisms that do not manifest any genetic
condition.2 74
Although current legislation is drafted in response to new technology
through constraints, moratoria, and prohibitions, they are shortsighted.
They close potential avenues of research by prohibiting techniques, by
limiting their scope and application to current issues, and by not addressing the application of new techniques. 275 Also, they fail to uniformly address privacy and social issues.
PART

IV:

PROPOSAL

' 276
"0 brave new world/ That has such people in it

Miranda, The Tempest, Act V, Scene I
Pharmacogenomics operates under the assumption that a genetic test
has been done and the genetic condition or disease determined is expressed. A uniform law addressing the use, distribution, and application
of genetic information may lessen public fear of potential third party discrimination. Such law must also address whether a physical impairment
is necessary for protection and whether the genetic information indicating
a predisposition to a disease or condition is deemed a pre-existing condition in the absence of a diagnosis based on other medical information of
such disease or condition. Defining who regulates the genetic informa271. Id. at 45-46.
272. Id. at 26.
273. Id. at 26, 46.
274. Id.
275. Bartha Maria Knoppers et al., Commercializationof Genetic Research and Public
Policy, 286 Sci. 2277, 2277 (1999).
276. The Complete Works of William Shakespeare, at http://the-tech.mit.edu/Shakespeare/tempest/tempest.5.1.html (last visited Mar. 27, 2003).
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tion, requiring informed consent, and pursuing strict compliance of the
law may also alleviate such fears. Uniform definitions in what constitutes
genetic discrimination and genetic information through broad language,
like the ADA, can guide in the application of nondiscrimination yet still
remain malleable in the application of the definitions.
PART V:

CONCLUSION

Before designer drugs can become a reality and be used for their intended purpose, the fears of those carrying genes that may be expressed
or already express some disorder or disease must be lessened. Maybe the
fully decoded human genome will prove that everyone has a predisposition to some sort of abnormality thereby eliminating any logical basis for
discrimination. But until humanity accepts the perceived differences
among populations as merely superficial, the creation of a comprehensive
uniform act that focuses on the distribution and control of genetic information may alleviate people's fears and help bring about the new era of
pharmacogenomics.
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